Author: "AGABITI‐ROSEI, E." / Topic: medicine.medical_specialty - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"AGABITI‐ROSEI, E."' showing total 57 results

Start Over Author "AGABITI‐ROSEI, E." Topic medicine.medical_specialty

57 results on '"AGABITI‐ROSEI, E."'

1. Validation of an easy questionnaire on the assessment of salt habit: the MINISAL-SIIA Study Program

Author: D’Elia, L., Manfredi, M., Strazzullo, P., Galletti, F., Agabiti-Rosei, E., Arcangeli, E., Artom, A., Barbato, A., Barbiero, M., Belfiore, A., Bernini, G., Boero, R., Berra, E., Biggi, A., Borgheresi, P., Borghi, C., Bosio, A., Caiazza, A., Caielli, P., Caló, L. A., Castellano, M., Catena, C., Cerrato, F., Cilia, C., Cipollini, F., Crippa, M., Cuspidi, C., D’Avino, M., De Giorgi, G. A., De Luca, N., De Pergola, G., Del Giudice, A., Desideri, G., Fallo, F., Ferri, C., Galeone, D., Garavelli, G., Gaudio, G., Giacchetti, G., Gidaro, B., Giovannetti, R., Grandi, A., Guglielmi, M., Iacoviello, L., Leonardis, D., Lonati, C., Lonati, L. M., Malatino, L., Mallamaci, F., Maresca, A. M., Marzano, L., Massara, C., Merletti, L., Meschi, M., Modesti, S., Montanari, A., Morganti, A., Musiari, L., Musso, N., Nardecchia, A., Nazzaro, P., Pallisco, O., Panichi, V., Parati, G., Pascale, C., Pini, C., Pirola, I., Pucci, G., Rabbia, F., Rescaldani, M., Ronchi, E., Rossi, E., Rossi, G., Sala, C., Sarzani, R., Sechi, L. A., Silvestris, F., Stancanelli, B., Trimarco, B., Ungar, A., Veglio, F., Veronesi, M., Vinella, L., D'Elia, L, Manfredi, M, Strazzullo, P, Galletti, F, Agabiti-Rosei, E, Arcangeli, E, Artom, A, Barbato, A, Barbiero, M, Belfiore, A, Bernini, G, Boero, R, Berra, E, Biggi, A, Borgheresi, P, Borghi, C, Bosio, A, Caiazza, A, Caielli, P, Calo, L, Castellano, M, Catena, C, Cerrato, F, Cilia, C, Cipollini, F, Crippa, M, Cuspidi, C, D'Avino, M, De Giorgi, G, De Luca, N, De Pergola, G, Del Giudice, A, Desideri, G, Fallo, F, Ferri, C, Galeone, D, Garavelli, G, Gaudio, G, Giacchetti, G, Gidaro, B, Giovannetti, R, Grandi, A, Guglielmi, M, Iacoviello, L, Leonardis, D, Lonati, C, Lonati, L, Malatino, L, Mallamaci, F, Maresca, A, Marzano, L, Massara, C, Merletti, L, Meschi, M, Modesti, S, Montanari, A, Morganti, A, Musiari, L, Musso, N, Nardecchia, A, Nazzaro, P, Pallisco, O, Panichi, V, Parati, G, Pascale, C, Pini, C, Pirola, I, Pucci, G, Rabbia, F, Rescaldani, M, Ronchi, E, Rossi, E, Rossi, G, Sala, C, Sarzani, R, Sechi, L, Silvestris, F, Stancanelli, B, Trimarco, B, Ungar, A, Veglio, F, Veronesi, M, Vinella, L, L. D’Elia, M. Manfredi, P. Strazzullo, F. Galletti, E. Agabiti-Rosei, E. Arcangeli, A. Artom, A. Barbato, M. Barbiero, A. Belfiore, G. Bernini, R. Boero, E. Berra, A. Biggi, P. Borgheresi, C. Borghi, A. Bosio, A. Caiazza, P. Caielli, L. A. Caló, M. Castellano, C. Catena, F. Cerrato, C. Cilia, F. Cipollini, M. Crippa, C. Cuspidi, M. D’Avino, G. A. De Giorgi, N. De Luca, G. De Pergola, A. Del Giudice, G. Desideri, F. Fallo, C. Ferri, D. Galeone, G. Garavelli, G. Gaudio, G. Giacchetti, B. Gidaro, R. Giovannetti, A. Grandi, M. Guglielmi, L. Iacoviello, D. Leonardi, C. Lonati, L. M. Lonati, L. Malatino, F. Mallamaci, A. M. Maresca, L. Marzano, C. Massara, L. Merletti, M. Meschi, S. Modesti, A. Montanari, A. Morganti, L. Musiari, N. Musso, A. Nardecchia, P. Nazzaro, O. Pallisco, V. Panichi, G. Parati, C. Pascale, C. Pini, I. Pirola, G. Pucci, F. Rabbia, M. Rescaldani, E. Ronchi, E. Rossi, G. Rossi, C. Sala, R. Sarzani, L. A. Sechi, F. Silvestri, B. Stancanelli, B. Trimarco, A. Ungar, F. Veglio, M. Veronesi, and L. Vinella
Subjects: Male, 0301 basic medicine, Validation study, medicine.medical_specialty, media_common.quotation_subject, Medicine (miscellaneous), 030209 endocrinology & metabolism, Nutrition and Dietetic, hypertension, sodium intake, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, Internal medicine, Nutrition and Dietetic, medicine, Humans, MINISAL-SIIA, Sodium Chloride, Dietary, Nutrition, media_common, 030109 nutrition & dietetics, Nutrition and Dietetics, Urinary sodium, business.industry, MINISAL-SIIA Study Program, Reproducibility of Results, Middle Aged, Anthropometry, Blood pressure, Italy, Hypertension, Dietary salt intake, Female, Habit, dietary salt intake, business, Dietetic, sodium intake
Abstract: Background/objectives: The aim of the present study was to validate a short questionnaire on habitual dietary salt intake, to quickly and easily identify individuals whose salt consumption exceeds recommended levels. Subjects/methods: A total of 1131 hypertensive subjects participating in the MINISAL-SIIA study were included in the analysis. Anthropometric indexes, blood pressure, and 24-h urinary sodium excretion (NaU) were measured. A fixed-sequence questionnaire on dietary salt intake was administered. Results: NaU was significantly associated with scores, with a linear association across categories (p for trend 85 mmol/day) and “very high NaU” (NaU > 170 mmol/day) was 86 and 35%, respectively. The score of the questionnaire had a significant ability to detect both “high NaU”—with a specificity of 95% at the score of 10 points—and “very high NaU”—with a specificity of 99.6% at score of 13 points. Conclusions: The main results of the study indicates that a higher score of this short questionnaire is distinctive of habitual high salt consumption in hypertensive patients.
Published: 2019

2. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment

Author: Danaei, G, Lu, Y, Singh, Gm, Carnahan, E, Stevens, Ga, Cowan, Mj, Farzadfar, F, Lin, Jk, Finucane, Mm, Rao, M, Khang, Yh, Riley, Lm, Mozaffarian, D, Lim, Ss, Ezzati, M, Aamodt, G, Abdeen, Z, Abdella, Na, Rahim, Hf, Addo, J, Aekplakorn, W, Afifi, Mm, Agabiti Rosei, E, Salinas, Ca, Agyemang, C, Ali, Mk, Ali, Mm, Al Nsour, M, Al Nuaim AR, Ambady, R, Di Angelantonio, E, Aro, P, Azizi, F, Babu, Bv, Bahalim, An, Barbagallo, Cm, Barbieri, Ma, Barceló, A, Barreto, Sm, Barros, H, Bautista, Le, Benetos, A, Bjerregaard, P, Björkelund, C, Bo, S, Bobak, M, Bonora, Enzo, Botana, Ma, Bovet, P, Breckenkamp, J, Breteler, Mm, Broda, G, Brown, Ij, Bursztyn, M, de León AC, Campos, H, Cappuccio, Fp, Capuano, V, Casiglia, E, Castellano, M, Castetbon, K, Cea, L, Chang, Cj, Chaouki, N, Chatterji, S, Chen, Cj, Chen, Z, Choi, Js, Chua, L, Cífková, R, Cobiac, Lj, Cooper, Rs, Corsi, Am, Costanza, Mc, Craig, Cl, Dankner, Rs, Dastgiri, S, Delgado, E, Dinc, G, Doi, Y, Dong, Gh, Dorsi, E, Dragano, N, Drewnowski, A, Eggertsen, R, Elliott, P, Engeland, A, Erem, C, Esteghamati, A, Fall, Ch, Fan, Jg, Ferreccio, C, Fezeu, L, Firmo, Jo, Florez, Hj, Fornés, Ns, Fowkes, Fg, Franceschini, G, Frisk, F, Fuchs, Fd, Fuller, El, Getz, L, Giampaoli, S, Gómez, Lf, Gomez Zumaquero JM, Graff Iversen, S, Grant, Jf, Carvajal, Rg, Gulliford, Mc, Gupta, R, Gupta, Pc, Gureje, O, Gutierrez, Hr, Hansen, Tw, Hata, J, He, J, Heim, N, Heinrich, J, Hemmingsson, T, Hennis, A, Herman, Wh, Herrera, Vm, Ho, S, Holdsworth, M, Frisman, Gh, Hopman, Wm, Hussain, A, Husseini, A, Ibrahim, Mm, Ikeda, N, Jacobsen, Bk, Jaddou, Hy, Jafar, Th, Janghorbani, M, Jasienska, G, Joffres, Mr, Jonas, Jb, Kadiki, Oa, Kalter Leibovici, O, Kamadjeu, Rm, Kaptoge, S, Karalis, I, Kastarinen, Mj, Katz, J, Keinan Boker, L, Kelly, P, Khalilzadeh, O, Kiechl, S, Kim, Kw, Kiyohara, Y, Kobayashi, J, Krause, Mp, Kubínová, R, Kurjata, P, Kusuma, Ys, Lam, Th, Langhammer, A, Lawes, Cm, Le, C, Lee, J, Lévy Marchal, C, Lewington, S, Li, Y, Lim, To, Lin, X, Lin, Cc, Lin, Hh, Lind, L, Lissner, L, Liu, X, Lopez Jaramillo, P, Lorbeer, R, Ma, G, Ma, S, Macià, F, Maclean, Dr, Maggi, S, Magliano, Dj, Makdisse, M, Mancia, G, Mannami, T, Marques Vidal, P, Mbanya, Jc, McFarlane Anderson, N, Miccoli, R, Miettola, J, Minh, Hv, Miquel, Jf, Miranda, Jj, Mohamed, Mk, Mohan, V, Mohanna, S, Mokdad, A, Mollentze, Wf, Morales, Dd, Morgan, K, Muiesan, Lm, Muntoni, S, Nabipour, I, Nakagami, T, Nangia, V, Nemesure, B, Neovius, M, Nerhus, Ka, Nervi, F, Neuhauser, H, Nguyen, M, Ninomiya, T, Noale, M, Oh, Sw, Ohkubo, T, Olivieri, Oliviero, Önal, Ae, Onat, A, Oróstegui, M, Ouedraogo, H, Pan, Wh, Panagiotakos, Db, Panza, F, Park, Y, Passos, Vm, Pednekar, Ms, Pelizzari, Pm, Peres, Ma, Pérez, C, Pérez Fernández, R, Pichardo, R, Phua, Hp, Pistelli, F, Plans, P, Polakowska, M, Poulter, N, Prabhakaran, D, Qiao, Q, Rafiei, M, Raitakari, Ot, Ramos, Lr, Rampal, S, Rampal, L, Rasmussen, F, Reddy, Kk, Redon, J, Revilla, L, Reyes García, V, Roaeid, Rb, Robinson, Ca, Rodriguez Artalejo, F, Rojas Martinez, R, Ronkainen, K, Rosero Bixby, L, Roth, Ga, Sachdev, Hs, Sánchez, Jr, Sanisoglu, Sy, Sans, S, Sarraf Zadegan, N, Scazufca, M, Schaan, Bd, Schapochnik, N, Schelleman, H, Schneider, Ij, Schooling, Cm, Schwarz, B, Sekuri, C, Sereday, Ms, Serra Majem, L, Shaw, J, Shera, As, Shi, Z, Shiri, R, Shu, Xo, Silva, Da, Silva, E, Simons, La, Smith, M, Söderberg, S, Soebardi, S, Solfrizzi, V, Sonestedt, E, Soysal, A, Stattin, P, Stein, Ad, Stergiou, Gs, Stessman, J, Sudo, A, Suka, M, Sundh, V, Sundquist, K, Sundström, J, Swai, Ab, Tai, Es, Tambs, K, Tesfaye, F, Thomas, Gn, Thorogood, M, Tilvis, Rs, Tobias, M, Torheim, Le, Trenkwalder, P, Tuomilehto, Jo, Tur, Ja, Tzourio, C, Uhernik, Ai, Ukoli, Fa, Unwin, N, Hoorn, Sv, Vanderpump, Mp, Varo, Jj, Veierød, Mb, Velásquez Meléndez, G, Verschuren, M, Viet, L, Villalpando, S, Vioque, J, Vollenweider, P, Volpato, S, Wang, N, Wang, Yx, Ward, M, Waspadji, S, Welin, Lx, Whitlock, G, Wilhelmsen, L, Willeit, J, Woodward, M, Wormser, D, Xavier, Aj, Xu, F, Xu, L, Yamamoto, A, Yang, G, Yang, X, Yeh, Lc, Yoon, Js, You, Q, Yu, Z, Zhang, J, Zhang, L, Zheng, W, Zhou, M, Ward, M., Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration, Danaei, G., Lu, Y., Singh, G.M., Carnahan, E., Stevens, G.A., Cowan, M.J., Farzadfar, F., Lin, J.K., Finucane, M.M., Rao, M., Khang, Y.H., Riley, L.M., Mozaffarian, D., Lim, S.S., Ezzati, M., Aamodt, G., Abdeen, Z., Abdella, N.A., Rahim, H.F., Addo, J., Aekplakorn, W., Afifi, M.M., Agabiti-Rosei, E., Salinas, C.A., Agyemang, C., Ali, M.K., Ali, M.M., Al-Nsour, M., Al-Nuaim, A.R., Ambady, R., Di Angelantonio, E., Aro, P., Azizi, F., Babu, B.V., Bahalim, A.N., Barbagallo, C.M., Barbieri, M.A., Barceló, A., Barreto, S.M., Barros, H., Bautista, L.E., Benetos, A., Bjerregaard, P., Björkelund, C., Bo, S., Bobak, M., Bonora, E., Botana, M.A., Bovet, P., Breckenkamp, J., Breteler, M.M., Broda, G., Brown, I.J., Bursztyn, M., de León, A.C., Campos, H., Cappuccio, F.P., Capuano, V., Casiglia, E., Castellano, M., Castetbon, K., Cea, L., Chang, C.J., Chaouki, N., Chatterji, S., Chen, C.J., Chen, Z., Choi, J.S., Chua, L., Cífková, R., Cobiac, L.J., Cooper, R.S., Corsi, A.M., Costanza, M.C., Craig, C.L., Dankner, R.S., Dastgiri, S., Delgado, E., Dinc, G., Doi, Y., Dong, G.H., Dorsi, E., Dragano, N., Drewnowski, A., Eggertsen, R., Elliott, P., Engeland, A., Erem, C., Esteghamati, A., Fall, C.H., Fan, J.G., Ferreccio, C., Fezeu, L., Firmo, J.O., Florez, H.J., Fornés, N.S., Fowkes, F.G., Franceschini, G., Frisk, F., Fuchs, F.D., Fuller, E.L., Getz, L., Giampaoli, S., Gómez, L.F., Gomez-Zumaquero, J.M., Graff-Iversen, S., Grant, J.F., Carvajal, R.G., Gulliford, M.C., Gupta, R., Gupta, P.C., Gureje, O., Gutierrez, H.R., Hansen, T.W., Hata, J., He, J., Heim, N., Heinrich, J., Hemmingsson, T., Hennis, A., Herman, W.H., Herrera, V.M., Ho, S., Holdsworth, M., Frisman, G.H., Hopman, W.M., Hussain, A., Husseini, A., Ibrahim, M.M., Ikeda, N., Jacobsen, B.K., Jaddou, H.Y., Jafar, T.H., Janghorbani, M., Jasienska, G., Joffres, M.R., Jonas, J.B., Kadiki, O.A., Kalter-Leibovici, O., Kamadjeu, R.M., Kaptoge, S., Karalis, I., Kastarinen, M.J., Katz, J., Keinan-Boker, L., Kelly, P., Khalilzadeh, O., Kiechl, S., Kim, K.W., Kiyohara, Y., Kobayashi, J., Krause, M.P., Kubínová, R., Kurjata, P., Kusuma, Y.S., Lam, T.H., Langhammer, A., Lawes, C.M., Le, C., Lee, J., Lévy-Marchal, C., Lewington, S., Li, Y., Lim, T.O., Lin, X., Lin, C.C., Lin, H.H., Lind, L., Lissner, L., Liu, X., Lopez-Jaramillo, P., Lorbeer, R., Ma, G., Ma, S., Macià, F., MacLean, D.R., Maggi, S., Magliano, D.J., Makdisse, M., Mancia, G., Mannami, T., Marques-Vidal, P., Mbanya, J.C., McFarlane-Anderson, N., Miccoli, R., Miettola, J., Minh, H.V., Miquel, J.F., Miranda, J.J., Mohamed, M.K., Mohan, V., Mohanna, S., Mokdad, A., Mollentze, W.F., Morales, D.D., Morgan, K., Muiesan, L.M., Muntoni, S., Nabipour, I., Nakagami, T., Nangia, V., Nemesure, B., Neovius, M., Nerhus, K.A., Nervi, F., Neuhauser, H., Nguyen, M., Ninomiya, T., Noale, M., Oh, S.W., Ohkubo, T., Olivieri, O., Önal, A.E., Onat, A., Oróstegui, M., Ouedraogo, H., Pan, W.H., Panagiotakos, D.B., Panza, F., Park, Y., Passos, V.M., Pednekar, M.S., Pelizzari, P.M., Peres, M.A., Pérez, C., Pérez-Fernández, R., Pichardo, R., Phua, H.P., Pistelli, F., Plans, P., Polakowska, M., Poulter, N., Prabhakaran, D., Qiao, Q., Rafiei, M., Raitakari, O.T., Ramos, L.R., Rampal, S., Rampal, L., Rasmussen, F., Reddy, K.K., Redon, J., Revilla, L., Reyes-García, V., Roaeid, R.B., Robinson, C.A., Rodriguez-Artalejo, F., Rojas-Martinez, R., Ronkainen, K., Rosero-Bixby, L., Roth, G.A., Sachdev, H.S., Sánchez, J.R., Sanisoglu, S.Y., Sans, S., Sarraf-Zadegan, N., Scazufca, M., Schaan, B.D., Schapochnik, N., Schelleman, H., Schneider, I.J., Schooling, C.M., Schwarz, B., Sekuri, C., Sereday, M.S., Serra-Majem, L., Shaw, J., Shera, A.S., Shi, Z., Shiri, R., Shu, X.O., Silva, D.A., Silva, E., Simons, L.A., Smith, M., Söderberg, S., Soebardi, S., Solfrizzi, V., Sonestedt, E., Soysal, A., Stattin, P., Stein, A.D., Stergiou, G.S., Stessman, J., Sudo, A., Suka, M., Sundh, V., Sundquist, K., Sundström, J., Swai, A.B., Tai, E.S., Tambs, K., Tesfaye, F., Thomas, G.N., Thorogood, M., Tilvis, R.S., Tobias, M., Torheim, L.E., Trenkwalder, P., Tuomilehto, J.O., Tur, J.A., Tzourio, C., Uhernik, A.I., Ukoli, F.A., Unwin, N., Hoorn, S.V., Vanderpump, M.P., Varo, J.J., Veierød, M.B., Velásquez-Meléndez, G., Verschuren, M., Viet, L., Villalpando, S., Vioque, J., Vollenweider, P., Volpato, S., Wang, N., Wang, Y.X., Ward, M., Waspadji, S., Welin, L.X., Whitlock, G., Wilhelmsen, L., Willeit, J., Woodward, M., Wormser, D., Xavier, A.J., Xu, F., Xu, L., Yamamoto, A., Yang, G., Yang, X., Yeh, L.C., Yoon, J.S., You, Q., Yu, Z., Zhang, J., Zhang, L., Zheng, W., Zhou, M., ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, Public and occupational health, Danaei G, Lu Y, Singh GM, Stevens GA, Cowan MJ, Farzadfar F, Lin JK, Finucane MM, Rao M, Khang Y-H, Riley LM, Mozaffarian D, Lim SS, Ezzati M, Aamodt G, Abdeen Z, Abdella NA, Abdul Rahim HF, Addo J, Aekplakorn W, Afi fi MM, Agabiti-Rosei E, Aguilar Salinas CA, Agyemang C, Ali MK, Ali MM, Al-Nsour M, Al-Nuaim AR, Ambady R, Di Angelantonio E, Aro P, Azizi F, Babu BV, Bahalim AN, Barbagallo CM, Barbieri MA, Barcelo A, Barreto SM, Barros H, Bautista LE, Benetos A, Bjerregaard P, Bjorkelund C, Bo S, Bobak M, Bonora E, Botana MA, Bovet P, Breckenkamp J, Breteler MM, Broda G, Brown IJ, Bursztyn M, Cabrera de Leon A, Campos H, Cappuccio FP, Capuano V, Casiglia E, Castellano M, Castetbon K, Cea L, Chang C-J, Chaouki N, Chatterji S, Chen C-J, Chen Z, Choi J-S, Chua L, Cifkova R, Cobiac LJ, Cooper RS, Corsi AM, Costanza MC, Craig CL, Dankner RS, Dastgiri S, Delgado E, Dinc G, Doi Y, Dong G-H, Dorsi E, Dragano N, Drewnowski A, Eggertsen R, Elliott P, Anders Engeland, Erem C, Esteghamati A, Fall CHD, Fan J-G, Ferreccio C, Fezeu L, Firmo JO, Florez HF, Fornes NF, Fowkes FGR, Franceschini G, Frisk F, Fuchs FD, Fuller EL, Getz L, Giampaoli S, Gomez LF, Gomez-Zumaquero JM, Graff –Iversen S, Grant JF, Guerrero Carvajal R, Gulliford MC, Gupta R, Gupta PC, Gureje O, Gutierrez HR, Hansen TW, Hata J, He J, Heim N, Heinrich J, Hemmingsson T, Hennis A, Herman WH, Herrera VM, Ho S, Holdsworth M, Hollman Frisman G, Hopman WM, Hussain A, Husseini A, Ibrahim MM, Ikeda N, Jacobsen BK, Jaddou HY, Jafar TH, Janghorbani M, Jasienska G, Joffres MR, Jonas JB, Kadiki OA, Kalter-Leibovici O, Kamadjeu RM, Kaptoge S, Karalis I, Kastarinen MJ, Katz J, Keinan-Boker L, Kelly P, Khalilzadeh O, Kiechl S, Woong Kim KW, Kiyohara Y, Kobayashi J, Krause MP, Kubinova R, Kurjata P, Kusuma YS, Lam TH, Langhammer A, Lawes CMM, Le C, Lee J, Levy-Marchal C, Lewington S, Li Y, Lim TO, Lin X, Lin C-C, Lin H-H, Lind L, Lissner L, Liu X, Lopez-Jaramillo P, Lorbeer R, Ma G, Ma S, Macia F, MacLean DR, Maggi S, Magliano DJ, Makdisse M, Mancia G, Mannami T, Marques-Vidal P, Mbanya JCN, McFarlane-Anderson N, Miccoli R, Miettola J, Minh HV, Miquel JF, J Miranda JJ, Mohamed MK, Mohan V, Mohanna S, Mokdad A, Mollentze WF, Morales DD, Morgan K, Muiesan LM, Muntoni S, Nabipour I, Nakagami T, Nangia V, Nemesure B, Neovius M, Nerhus KA, Nervi F, Neuhauser H, Nguyen M, Ninomiya T, Noale M, Oh SW, Ohkubo T, Olivieri O, Onal AE, Onat A, Orostegui M, Ouedraogo H, Pan W-A, Panagiotakos DB, Panza F, Park Y, Passos VMA, Pednekar MS, Pelizzari PM, Peres MA, Perez C, Perez-Fernandez R, Pichardo R, Hwee Pin Phua, Francesco Pistelli, Plans P, Polakowska M, Poulter N, Prabhakaran D, Qiao Q, Rafiei M, Raitakari OT, Ramos LR, Rampal S, Rampal L, Rasmussen F, Reddy KKR, Josep Redon J, Revilla L, Reyes-GarciaV, Roaeid RB, Robinson CA, Rodriguez-Artalejo F, Rojas-Martinez R, Ronkainen K, Rosero-Bixby L, Roth GA, Sachdev HS, Sanchez JR, Sanisoglu SY, Sans S, Sarraf-Zadegan N, Scazufca M, Schaan BD, Schapochnik N, Schelleman H, Schneider IJC, Schooling CM, Schwarz B, Sekuri C, Sereday MS, Serra-Majem L, Shaw J, Shera AS, Shi Z, Shiri R, Shu XO, Santos Silva DA, Silva E, Simons LA, Smith M, Soderberg S, Soebardi S, Solfrizzi V, Sonestedt E, Soysal A, StattinP, Stein AD, Stergiou GS, Stessman J, Sudo A, Suka M, Sundh V, Sundquist K, Sundstrom J, Swai AB, Tai ES, Tambs K, Tesfaye F, Thomas GN, Thorogood M, Tilvis RS, Tobias M, Torheim LE, Trenkwalder P, Tuomilehto JO, Tur JA, Tzourio C, Uhernik A, Ukoli FA, Unwin N, Vander Hoorn S, Vanderpump MP, Varo JJ, Veierod MB, Velasquez-Melendez G, Verschuren M, Viet L, Villalpando S, Vioque J, Vollenweider P, Volpato S, Wang N, Wang YX, Ward M, Waspadji S, Welin LX, Whitlock G, Wilhelmsen L, Willeit J, Woodward M, Wormser D, Xavier AJ, Xu F, Xu L, Yamamoto A, Yang G, Yang X, Yeh L-C, Yoon J-S, You Q, Yu Z, Zhang J, Zhang L, Zheng W, Zhou M, Danaei, G, Lu, Y, Singh, G, Carnahan, E, Stevens, G, Cowan, M, Farzadfar, F, Lin, J, Finucane, M, Rao, M, Khang, Y, Riley, L, Arian, D, Lim, S, Ezzati, M, Aamodt, G, Abdeen, Z, Abdella, N, Rahim, H, Addo, J, Aekplakorn, W, Afifi, M, Agabiti-Rosei, E, Salinas, C, Agyemang, C, Ali, M, Al-Nsour, M, Al-Nuaim, A, Ambady, R, Angelantonio, E, Aro, P, Azizi, F, Babu, B, Bahalim, A, Barbagallo, C, Barbieri, M, Barceló, A, Barreto, S, Barros, H, Bautista, L, Benetos, A, Bjerregaard, P, Björkelund, C, Bo, S, Bobak, M, Bonora, E, Botana, M, Bovet, P, Breckenkamp, J, Breteler, M, Broda, G, Brown, I, Bursztyn, M, de León, A, Campos, H, Cappuccio, F, Capuano, V, Casiglia, E, Castellano, M, Castetbon, K, Cea, L, Chang, C, Chaouki, N, Chatterji, S, Chen, C, Chen, Z, Choi, J, Chua, L, Cífková, R, Cobiac, L, Cooper, R, Corsi, A, Costanza, M, Craig, C, Dankner, R, Dastgiri, S, Delgado, E, Dinc, G, Doi, Y, Dong, G, Dorsi, E, Dragano, N, Drewnowski, A, Eggertsen, R, Elliott, P, Engeland, A, Erem, C, Esteghamati, A, Fall, C, Fan, J, Ferreccio, C, Fezeu, L, Firmo, J, Florez, H, Fornés, N, Fowkes, F, Franceschini, G, Frisk, F, Fuchs, F, Fuller, E, Getz, L, Giampaoli, S, Gómez, L, Gomez-Zumaquero, J, Iversen, S, Grant, J, Carvajal, R, Gulliford, M, Gupta, R, Gupta, P, Gureje, O, Gutierrez, H, Hansen, T, Hata, J, He, J, Heim, N, Heinrich, J, Hemmingsson, T, Hennis, A, Herman, W, Herrera, V, Ho, S, Holdsworth, M, Frisman, G, Hopman, W, Hussain, A, Husseini, A, Ibrahim, M, Ikeda, N, Jacobsen, B, Jaddou, H, Jafar, T, Janghorbani, M, Jasienska, G, Joffres, M, Jonas, J, Kadiki, O, Kalter-Leibovici, O, Kamadjeu, R, Kaptoge, S, Karalis, I, Kastarinen, M, Katz, J, Keinan-Boker, L, Kelly, P, Khalilzadeh, O, Kiechl, S, Kim, K, Kiyohara, Y, Kobayashi, J, Krause, M, Kubínová, R, Kurjata, P, Kusuma, Y, Lam, T, Langhammer, A, Lawes, C, Le, C, Lee, J, Lévy-Marchal, C, Lewington, S, Li, Y, Lim, T, Lin, X, Lin, C, Lin, H, Lind, L, Lissner, L, Liu, X, Lopez-Jaramillo, P, Lorbeer, R, Ma, G, Ma, S, Macià, F, Maclean, D, Maggi, S, Magliano, D, Makdisse, M, Mancia, G, Mannami, T, Marques-Vidal, P, Mbanya, J, McFarlane-Anderson, N, Miccoli, R, Miettola, J, Minh, H, Miquel, J, Miranda, J, Mohamed, M, Mohan, V, Mohanna, S, Mokdad, A, Mollentze, W, Morales, D, Morgan, K, Lorenza M Muiesan, N, Muntoni, S, Nabipour, I, Nakagami, T, Nangia, V, Nemesure, B, Neovius, M, Nerhus, K, Nervi, F, Neuhauser, H, Nguyen, M, Ninomiya, T, Noale, M, Oh, S, Ohkubo, T, Olivieri, O, Önal, A, Onat, A, Oróstegui, M, Ouedraogo, H, Pan, W, Panagiotakos, D, Panza, F, Park, Y, Passos, V, Pednekar, M, Pelizzari, P, Peres, M, Cynthia Pérez, N, Pérez-Fernández, R, Pichardo, R, Phua, H, Pistelli, F, Plans, P, Polakowska, M, Poulter, N, Prabhakaran, D, Qiao, Q, Rafiei, M, Raitakari, O, Ramos, L, Rampal, S, Rampal, L, Rasmussen, F, Reddy, K, Redon, J, Revilla, L, Reyes-García, V, Roaeid, R, Robinson, C, Rodriguez-Artalejo, F, Rojas-Martinez, R, Ronkainen, K, Rosero-Bixby, L, Roth, G, Sachdev, H, Sánchez, J, Sanisoglu, S, Sans, S, Sarraf-Zadegan, N, Scazufca, M, Schaan, B, Schapochnik, N, Schelleman, H, Schneider, I, Schooling, C, Schwarz, B, Sekuri, C, Sereday, M, Serra-Majem, L, Shaw, J, Shera, A, Shi, Z, Shiri, R, Shu, X, Silva, D, Silva, E, Simons, L, Smith, M, Söderberg, S, Soebardi, S, Solfrizzi, V, Sonestedt, E, Soysal, A, Stattin, P, Stein, A, Stergiou, G, Stessman, J, Sudo, A, Suka, M, Sundh, V, Sundquist, K, Sundström, J, Swai, A, Tai, E, Tambs, K, Tesfaye, F, Thomas, G, Thorogood, M, Tilvis, R, Tobias, M, Torheim, L, Trenkwalder, P, Tuomilehto, J, Tur, J, Tzourio, C, Uhernik, A, Ukoli, F, Unwin, N, Hoorn, S, Vanderpump, M, Varo, J, Veierød, M, Velásquez-Meléndez, G, Verschuren, M, Viet, L, Villalpando, S, Vioque, J, Vollenweider, P, Volpato, S, Wang, N, Wang, Y, Ward, M, Waspadji, S, Lennart X Welin, N, Whitlock, G, Wilhelmsen, L, Willeit, J, Woodward, M, Wormser, D, André J Xavier, N, Xu, F, Xu, L, Yamamoto, A, Yang, G, Yang, X, Yeh, L, Yoon, J, You, Q, Yu, Z, Zhang, J, Zhang, L, Zheng, W, and Zhou, M
Subjects: Male, Settore MED/09 - Medicina Interna, kidney disease, Endocrinology, Diabetes and Metabolism, humanos, coste de las enfermedades, Disease, Global Health, Cohort Studies, Endocrinology, Cost of Illness, cardiovascular disease, Health Transition, Risk Factors, transición sanitaria, estudios prospectivos, Renal Insufficiency, Chronic -- complications -- epidemiology -- mortality, evaluación de riesgos, Renal Insufficiency, Prospective Studies, Chronic, estudios de cohortes, Metabolic Syndrome, education.field_of_study, diabetes, Mortality rate, Age Factors, Cardiovascular Diseases, Diabetes Complications, Female, Health Surveys, Humans, Metabolic Syndrome X, Renal Insufficiency, Chronic, Risk Assessment, Sex Factors, Spatio-Temporal Analysis, Internal Medicine, Cardiovascular Diseases -- complications -- epidemiology -- mortality, Cardiovascular disease,Diabetes Mellitus, chronic kidney disease, Diabetes Complications -- epidemiology -- mortality, Sciences bio-médicales et agricoles, Diabetes and Metabolism, encuestas de salud, análisis temporoespacial, Risk assessment, complicaciones de la diabetes, insuficiencia renal, medicine.medical_specialty, Cardiovascular disease, diabetes mortality, Population, enfermedades cardiovasculares, Metabolic Syndrome X -- complications -- epidemiology -- mortality, Article, chronic kidney disease, mortality, Internal medicine, Environmental health, Diabetes mellitus, medicine, factores de riesgo, Risk factor, education, business.industry, medicine.disease, Relative risk, Cardiovascular Diseases/complications, Cardiovascular Diseases/epidemiology, Cardiovascular Diseases/mortality, Diabetes Complications/epidemiology, Diabetes Complications/mortality, Metabolic Syndrome X/complications, Metabolic Syndrome X/epidemiology, Metabolic Syndrome X/mortality, Renal Insufficiency, Chronic/complications, Renal Insufficiency, Chronic/epidemiology, Renal Insufficiency, Chronic/mortality, business, Kidney disease
Abstract: High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010., 0, info:eu-repo/semantics/published
Published: 2014

3. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome

Author: Van Bortel, L, Boutouyrie, P, Laurent, S, Pannier, B, Zannad, F, Schmieder, R, Agabiti Rosei, E, Stehouwer, C, Cockcroft, J, Wilkinson, I., GIANNATTASIO, CRISTINA, MANCIA, GIUSEPPE, Van Bortel, L, Boutouyrie, P, Laurent, S, Pannier, B, Zannad, F, Schmieder, R, Agabiti Rosei, E, Giannattasio, C, Mancia, G, Stehouwer, C, Cockcroft, J, Wilkinson, I, MUMC+: HVC Pieken Maastricht Studie (9), Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), and RS: CARIM - R3 - Vascular biology
Subjects: medicine.medical_specialty, hypertension, Carotid arteries, compliance, arteries, Internal medicine, medicine.artery, Internal Medicine, medicine, Pulse wave velocity, Aorta, business.industry, blood pressure, arterie, antihypertensive agents, medicine.disease, Compliance (physiology), aorta, Blood pressure, Endocrinology, randomized controlled trial, Cardiology, antihypertensive agent, Aortic stiffness, Metabolic syndrome, business, Olmesartan, medicine.drug
Abstract: Whether angiotensin receptor blockers can dose-dependently remodel the arterial wall during long-term treatment has been largely debated. In this phase III, multicenter, randomized, double-blind, parallel-group study, 133 subjects with hypertension and metabolic syndrome were assigned to olmesartan, either 20 mg (n=44), 40 mg (n=42), or 80 mg (n=47) once a day, according to a force titration design during a 1-year period. Office blood pressure, 24-hour blood pressure, aortic stiffness (carotid-femoral pulse wave velocity), and carotid parameters were measured at baseline, 24 weeks, and 52 weeks. Pulse wave velocity significantly decreased ( P P =0.0685) for a smaller effect of 20 mg, compared with 40 and 80 mg at week 52. When the 40 and 80 mg doses were combined (40/80 mg versus 20 mg), a significant blood pressure–independent reduction in pulse wave velocity (−0.61 m/s) was observed at week 52 ( P =0.0066), whereas the nonadjusted reduction was −1.31 m/s ( P
Published: 2014

4. Excess dietary sodium and inadequate potassium intake by hypertensive patients in Italy: results of the MINISAL-SIIA study program

Author: Galletti, F, Agabiti Rosei, E, Bernini, G, Boero, R, Desideri, G, Fallo, F, Mallamaci, F, Morganti, A, Castellano, M, Nazzaro, P, Trimarco, B, Strazzullo, P, Campanozzi, A, Carcea, M, Donfrancesco, C, Galeone, D, Giampaoli, S, Iacoviello, L, Scalfi, L, Siani, A, Modesti, S, Parini, U, Pascale, C, Bosio, A, Cerrato, F, Pallisco, O, Massara, C, Veglio, Franco, Rabbia, F, Testa, E, Musso, N, Martino, S, Artom, A, Pirola, I, Parati, G, Lonati, Lm, Cuspidi, C, Sala, C, Rescaldani, M, Gidaro, B, Lonati, C, Grandi, A, Maresca, Am, Merletti, L, Garavelli, G, Pini, C, Crippa, M, Lazzari, F, Ronchi, E, Gaudio, G, Caló, La, Caielli, P, Rossi, G, Sechi, La, Marzano, L, Catena, C, Ungar, A, Giovannetti, R, Cipollini, F, Arcangeli, E, Borgheresi, P, Panichi, V, Rossi, E, Borghi, C, Veronesi, M, Biggi, A, Musiari, L, Montanari, A, Caiazza, A, Meschi, M, Sarzani, R, Giacchetti, G, Schillaci, G, Pucci, G, Ferri, C, Mezzetti, A, Rinaldi, Po, De Luca, N, Barbato, A, Fazio, V, D'Avino, M, Guglielmi, M, De Giorgi GA, Del Giudice, A, Belfiore, A, Barbiero, M, Murri, A, Nardecchia, A, De Pergola, G, Silvestris, F, Vinella, L, Leonardis, D, Malatino, L, Stancanelli, B, Cilia, C., Galletti, F, Agabiti-Rosei, E, Bernini, G, Boero, R, Desideri, G, Fallo, F, Mallamaci, F, Morganti, A, Castellano, M, Nazzaro, P, Trimarco, B, Strazzullo, P, Borghi, C, and Veronesi, M
Subjects: Adult, Male, medicine.medical_specialty, Potassium intake, Physiology, Potassium, Sodium, chemistry.chemical_element, Blood Pressure, Nutrition Policy, Young Adult, Dietary Sodium, Internal medicine, Internal Medicine, medicine, salt, Humans, Blood pressure, Diet, Hypertension, Aged, business.industry, hypertension, Potassium, Dietary, Sodium, Dietary, Anthropometry, Middle Aged, Endocrinology, chemistry, Italy, Female, Cardiology and Cardiovascular Medicine, business
Abstract: INTRODUCTION:The aim of the study was to assess the age-specific, sex-specific, and region-specific average sodium and potassium intake and its association with anthropometric characteristics in a sample of the Italian adult hypertensive population. METHODS:A total of 1232 hypertensive patients were recruited consecutively by 47 centers recognized by the Italian Society of Hypertension. The enrolled participants were on stable antihypertensive treatment. Anthropometric indices, blood pressure, 24-h urinary sodium, and potassium excretion were measured and used as proxy for the average daily sodium and potassium intake. RESULTS:The average sodium intake was 172 mmol (or 10.1 g of salt/day) among men and 138 (or 8.1) among women, with no difference among geographical areas. Over 90% of men and 81% of women had a consumption higher than the recommended standard dietary intake of 5 g/day. The average potassium intake was 63 and 56 mmol, respectively in men and women, again without geographical differences, nearly 92% of men and 95% of women having an intake lower than the recommended intake (100 mmol/day or 3.9 g/day). There was a significant trend to a gradual decrease in sodium intake with age in both sexes (P
Published: 2013

5. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

Author: Trimarco, THE TELMISARTAN RANDOMISED ASSESSMENT STUDY IN ACE INTOLERANT SUBJECTS WITH CARDIOVASCULAR DISEASE TRANSCEND INVESTIGATORS Italy: B., Verdecchia, P., Maggioni, A., Achilli, A., Agabiti Rosei, E., Ambrosio, Gb, Bentivoglio, M., Branzi, A., Chersevani, D., Chiariello, M., Cirrincione, V., Dembech, C., Ferrari, R., Gattobigio, R., Giovannini, E., Lauro, R., Lembo, Giuseppe, Moretti, L., Pancaldi, L., Pede, S., Pettinati, G., Reboldi, G., Ricci, R., Rosiello, G., Rozza, F., Sardone, Mg, Tavazzi, L., Terrosu, P., Venco, A., Vetrano, A., and Volpe, Massimo
Subjects: Male, medicine.medical_specialty, Angiotensin-Converting Enzyme Inhibitors, Kaplan-Meier Estimate, Klinikai orvostudományok, Placebo, Benzoates, law.invention, Randomized controlled trial, law, Internal medicine, medicine, Humans, Single-Blind Method, Telmisartan, Myocardial infarction, Angioedema, Stroke, Aged, Intention-to-treat analysis, biology, business.industry, Angiotensin-converting enzyme, Orvostudományok, General Medicine, medicine.disease, ACE inibitori, AT1 bloccanti, trial clinico, Candesartan, Cough, Therapeutic Equivalency, Cardiovascular Diseases, Anesthesia, biology.protein, Benzimidazoles, Female, Hypotension, business, Risk Reduction Behavior, Follow-Up Studies, medicine.drug
Abstract: BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage. METHODS: After a 3-week run-in period, 5926 patients, many of whom were receiving concomitant proven therapies, were randomised to receive telmisartan 80 mg/day (n=2954) or placebo (n=2972) by use of a central automated randomisation system. Randomisation was stratified by hospital. The primary outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00153101. FINDINGS: The median duration of follow-up was 56 (IQR 51-64) months. All randomised patients were included in the efficacy analyses. Mean blood pressure was lower in the telmisartan group than in the placebo group throughout the study (weighted mean difference between groups 4.0/2.2 [SD 19.6/12.0] mm Hg). 465 (15.7%) patients experienced the primary outcome in the telmisartan group compared with 504 (17.0%) in the placebo group (hazard ratio 0.92, 95% CI 0.81-1.05, p=0.216). One of the secondary outcomes-a composite of cardiovascular death, myocardial infarction, or stroke-occurred in 384 (13.0%) patients on telmisartan compared with 440 (14.8%) on placebo (0.87, 0.76-1.00, p=0.048 unadjusted; p=0.068 after adjustment for multiplicity of comparisons and overlap with primary outcome). 894 (30.3%) patients receiving telmisartan were hospitalised for a cardiovascular reason, compared with 980 (33.0%) on placebo (relative risk 0.92, 95% CI 0.85-0.99; p=0.025). Fewer patients permanently discontinued study medication in the telmisartan group than in the placebo group (639 [21.6%] vs 705 [23.8%]; p=0.055); the most common reason for permanent discontinuation was hypotensive symptoms (29 [0.98%] in the telmisartan group vs 16 [0.54%] in the placebo group). INTERPRETATION: Telmisartan was well tolerated in patients unable to tolerate ACE inhibitors. Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke. FUNDING: Boehringer Ingelheim.
Published: 2008

6. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008

Author: Danaei, G., Singh, G., Paciorek, C., Lin, J., Cowan, M., Finucane, M., Farzadfar, F., Stevens, G., Riley, L., Lu, Y., Rao, M., Ezzati, M., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group, Aamodt, G., Abdeen, Z., Abdella, N., Rahim, H., Addo, J., Aekplakorn, W., Afifi, M., Agabiti Rosei, E., Aguilar Salinas CA, Agyemang, C., Ali, M., Al Nsour, M., Al Nuaim AR, Ambady, R., Aro, P., Azizi, F., Barbagallo, C., Barbieri, M., Barceló, A., Barreto, S., Barros, H., Bautista, L., Benetos, A., Bjerregaard, P., Björkelund, C., Bo, S., Bobak, M., Bonora, E., Bontha, B., Botana, M., Bovet, P., Breckenkamp, J., Breteler, M., Broda, G., Brown, I., Bursztyn, M., Cabrera de León, A., Campos, H., Cappuccio, F., Capuano, V., Casiglia, E., Castellano, M., Castetbon, K., Cea, L., Chang, C., Chaouki, N., Chatterji, S., Chen, Z., Chen, C., Choi, J., Chua, L., Cífková, R., Cobiac, L., Cooper, R., Corsi, A., Costanza, M., Craig, C., Dankner, R., Dastgiri, S., Delgado, E., Dinc, G., Doi, Y., Dong, G., Dorsi, E., Dragano, N., Drewnowski, A., Eggertsen, W., Elliott, P., Engeland, A., Erem, C., Esteghamati, A., Fall, C., Fan, J., Ferreccio, C., Fezeu, L., Firmo, J., Florez, H., Fornés, N., Fowkes, F., Franceschini, G., Frisk, F., Fuchs, F., Fuller, E., Getz, L., Giampaoli, S., Gómez, L., Gomez Zumaquero JM, Graff Iversen, S., Grant, J., Guerrero Carvajal, R., Gulliford, M., Gupta, R., Gupta, P., Gureje, O., Hansen, T., Hata, J., He, J., Heim, N., Heinrich, J., Hemmingsson, T., Hennis, A., Herman, W., Herrera, V., Ho, S., Holdsworth, M., Hollman Frisman, G., Hopman, W., Hussain, A., Husseini, A., Ibrahim, M., Ikeda, N., Jacobsen, B., Jaddou, H., Jafar, T., Janghorbani, M., Jasienska, G., Joffres, M., Jonas, J., Kadiki, O., Kalter Leibovici, O., Kamadjeu, R., Karalis, I., Kastarinen, M., Katz, J., Keinan Boker, L., Kelly, P., Khalilzadeh, O., Khang, Y., Kiechl, S., Kim, K., Kiyohara, Y., Kobayashi, J., Krause, M., Kubínová, R., Kurjata, P., Kusuma, Y., Lam, T., Langhammer, A., Lawes, C., Le, C., Lee, J., Lévy Marchal, C., Li, Y., Lim, S., Lim, T., Lin, X., Lin, C., Lin, H., Lind, L., Lissner, L., Liu, X., Lopez Jaramillo, P., Lorbeer, R., Ma, G., Ma, S., Macià, F., Maclean, D., Maggi, S., Magliano, D., Makdisse, M., Mancia, G., Mannami, T., Marques Vidal, P., Mbanya, J., McFarlane Anderson, N., Miccoli, R., Miettola, J., Minh, H., Miquel, J., Miranda, J., Mohamed, M., Mohan, V., Mohanna, S., Mokdad, A., Mollentze, W., Morales, D., Morgan, K., Muiesan, L., Muntoni, S., Nabipour, I., Nakagami, T., Nangia, V., Nemesure, B., Neovius, M., Nerhus, K., Nervi, F., Neuhauser, H., Nguyen, M., Ninomiya, T., Noale, M., Oh, S., Ohkubo, T., Olivieri, O., Önal, A., Onat, A., Oróstegui, M., Ouedraogo, H., Pan, W., Panagiotakos, D., Panza, F., Park, Y., Passos, V., Pednekar, M., Peres, M., Pérez, C., Pérez Fernández, R., Pichardo, R., Phua, H., Pistelli, F., Plans, P., Polakowska, M., Poulter, N., Prabhakaran, D., Qiao, Q., Rafiei, M., Raitakari, O., Ramos, L., Rampal, S., Rampal, L., Rasmussen, F., Reddy, K., Redon, J., Revilla, L., Reyes García, V., Roaeid, R., Rodriguez Artalejo, F., Rojas Martinez, R., Ronkainen, K., Rosero Bixby, L., Roth, G., Sachdev, H., Sánchez, J., Sanisoglu, S., Sans, S., Sarraf Zadegan, N., Scazufca, M., Schaan, B., Schapochnik, N., Schelleman, H., Schneider, I., Schooling, C., Schwarz, B., Sekuri, C., Sereday, M., Serra Majem, L., Shaw, J., Shera, A., Shi, Z., Shiri, R., Shu, X., Silva, D., Silva, E., Simons, L., Smith, M., Söderberg, S., Soebardi, S., Solfrizzi, V., Sonestedt, E., Soysal, A., Stattin, P., Stein, A., Stergiou, G., Stessman, J., Sudo, A., Suka, M., Sundh, V., Sundquist, K., Sundström, J., Swai, A., Tai, E., Tambs, K., Tesfaye, F., Thomas, G., Thorogood, M., Tilvis, R., Tobias, M., Torheim, L., Trenkwalder, P., Tuomilehto, J., Tur, J., Tzourio, C., Uhernik, A., Ukoli, F., Unwin, N., Vander Hoorn, S., Vanderpump, M., Varo, J., Veierød, B., Velásquez Meléndez, G., Verschuren, M., Viet, L., Villalpando, S., Vioque, J., Vollenweider, P., Volpato, S., Wang, N., Wang, Y., Ward, M., Waspadji, S., Welin, L., Wilhelmsen, L., Willeit, J., Woodward, M., Xavier, A., Xu, F., Xu, L., Yamamoto, A., Yang, G., Yang, X., Yeh, L., Yoon, J., You, Q., Yu, Z., Zhang, J., Zhang, L., Zheng, W., Zhou, M., Danaei G, Singh GM, Paciorek CJ, Lin JK, Cowan MJ, Finucane MM, Farzadfar F, Stevens GA, Riley LM, Lu Y, Rao M, Ezzati M and Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group, Aamodt G, Abdeen Z, Abdella NA, Rahim HF, Addo J, Aekplakorn W, Afifi MM, Agabiti-Rosei E, Aguilar Salinas CA, Agyemang C, Ali MM, Al-Nsour M, Al-Nuaim AR, Ambady R, Aro P, Azizi F, Barbagallo CM, Barbieri MA, Barceló A, Barreto SM, Barros H, Bautista LE, Benetos A, Bjerregaard P, Björkelund C, Bo S, Bobak M, Bonora E, Bontha BV, Botana MA, Bovet P, Breckenkamp J, Breteler MM, Broda G, Brown IJ, Bursztyn M, Cabrera de León A, Campos H, Cappuccio FP, Capuano V, Casiglia E, Castellano M, Castetbon K, Cea L, Chang CJ, Chaouki N, Chatterji S, Chen Z, Chen CJ, Choi JS, Chua L, Cífková R, Cobiac LJ, Cooper RS, Corsi AM, Costanza MC, Craig CL, Dankner RS, Dastgiri S, Delgado E, Dinc G, Doi Y, Dong GH, Dorsi E, Dragano N, Drewnowski A, Eggertsen W, Elliott P, Engeland A, Erem C, Esteghamati A, Fall CH, Fan JG, Ferreccio C, Fezeu L, Firmo JO, Florez HJ, Fornés NS, Fowkes FG, Franceschini G, Frisk F, Fuchs FD, Fuller EL, Getz L, Giampaoli S, Gómez LF, Gomez-Zumaquero JM, Graff-Iversen S, Grant JF, Guerrero Carvajal R, Gulliford MC, Gupta R, Gupta PC, Gureje O, Hansen TW, Hata J, He J, Heim N, Heinrich J, Hemmingsson T, Hennis A, Herman WH, Herrera VM, Ho S, Holdsworth M, Hollman Frisman G, Hopman WM, Hussain A, Husseini A, Ibrahim M, Ikeda N, Jacobsen BK, Jaddou HY, Jafar TH, Janghorbani M, Jasienska G, Joffres MR, Jonas JB, Kadiki OA, Kalter-Leibovici O, Kamadjeu RM, Karalis I, Kastarinen MJ, Katz J, Keinan-Boker L, Kelly P, Khalilzadeh O, Khang YH, Kiechl S, Kim KW, Kiyohara Y, Kobayashi J, Krause MP, Kubínová R, Kurjata P, Kusuma YS, Lam TH, Langhammer A, Lawes CM, Le C, Lee J, Lévy-Marchal C, Li Y, Lim S, Lim TO, Lin X, Lin CC, Lin HH, Lind L, Lissner L, Liu X, Lopez-Jaramillo P, Lorbeer R, Ma G, Ma S, Macià F, MacLean DR, Maggi S, Magliano DJ, Makdisse M, Mancia G, Mannami T, Marques-Vidal P, Mbanya JC, McFarlane-Anderson N, Miccoli R, Miettola J, Minh HV, Miquel JF, Miranda J, Mohamed MK, Mohan V, Mohanna S, Mokdad A, Mollentze WF, Morales DD, Morgan K, Muiesan LM, Muntoni S, Nabipour I, Nakagami T, Nangia V, Nemesure B, Neovius M, Nerhus KA, Nervi F, Neuhauser H, Nguyen M, Ninomiya T, Noale M, Oh SW, Ohkubo T, Olivieri O, Önal AE, Onat A, Oróstegui M, Ouedraogo H, Pan WH, Panagiotakos DB, Panza F, Park Y, Passos VM, Pednekar MS, Peres MA, Pérez C, Pérez-Fernández R, Pichardo R, Phua HP, Pistelli F, Plans P, Polakowska M, Poulter N, Prabhakaran D, Qiao Q, Rafiei M, Raitakari OT, Ramos LR, Rampal S, Rampal L, Rasmussen F, Reddy KK, Redon J, Revilla L, Reyes-García V, Roaeid RB, Rodriguez-Artalejo F, Rojas-Martinez R, Ronkainen K, Rosero-Bixby L, Roth GA, Sachdev HS, Sánchez JR, Sanisoglu SY, Sans S, Sarraf-Zadegan N, Scazufca M, Schaan BD, Schapochnik N, Schelleman H, Schneider IJ, Schooling C, Schwarz B, Sekuri C, Sereday MS, Serra-Majem L, Shaw J, Shera AS, Shi Z, Shiri R, Shu XO, Silva DA, Silva E, Simons LA, Smith M, Söderberg S, Soebardi S, Solfrizzi V, Sonestedt E, Soysal A, Stattin P, Stein AD, Stergiou GS, Stessman J, Sudo A, Suka M, Sundh V, Sundquist K, Sundström J, Swai AB, Tai E, Tambs K, Tesfaye F, Thomas GN, Thorogood M, Tilvis RS, Tobias M, Torheim LE, Trenkwalder P, Tuomilehto JO, Tur JA, Tzourio C, Uhernik AI, Ukoli FA, Unwin N, Vander Hoorn S, Vanderpump MP, Varo JJ, Veierød B, Velásquez-Meléndez G, Verschuren M, Viet L, Villalpando S, Vioque J, Vollenweider P, Volpato S, Wang N, Wang YX, Ward M, Waspadji S, Welin LX, Wilhelmsen L, Willeit J, Woodward M, Xavier AJ, Xu F, Xu L, Yamamoto A, Yang G, Yang X, Yeh LC, Yoon JS, You Q, Yu Z, Zhang J, Zhang L, Zheng W, Zhou M, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, and Public and occupational health
Subjects: Gerontology, Adult, Male, Risk, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Measures of national income and output, Population, Hypercholesterolemia, OBESIDADE, Blood Pressure, Global Health, Body Mass Index, Age Distribution, Risk Factors, cardiovascular disease, Physiology (medical), Diabetes mellitus, risk factors, Epidemiology, medicine, Diabetes Mellitus, Humans, Obesity, Risk factor, Sex Distribution, education, Developing Countries, Cholesterolo, education.field_of_study, business.industry, Urbanization, Feeding Behavior, Middle Aged, medicine.disease, Blood pressure, Cholesterol, Socioeconomic Factors, Cardiovascular Diseases, Hypertension, Western World, Female, Cardiology and Cardiovascular Medicine, business, Body mass index, Demography
Abstract: Background— It is commonly assumed that cardiovascular disease risk factors are associated with affluence and Westernization. We investigated the associations of body mass index (BMI), fasting plasma glucose, systolic blood pressure, and serum total cholesterol with national income, Western diet, and, for BMI, urbanization in 1980 and 2008. Methods and Results— Country-level risk factor estimates for 199 countries between 1980 and 2008 were from a previous systematic analysis of population-based data. We analyzed the associations between risk factors and per capita national income, a measure of Western diet, and, for BMI, the percentage of the population living in urban areas. In 1980, there was a positive association between national income and population mean BMI, systolic blood pressure, and total cholesterol. By 2008, the slope of the association between national income and systolic blood pressure became negative for women and zero for men. Total cholesterol was associated with national income and Western diet in both 1980 and 2008. In 1980, BMI rose with national income and then flattened at ≈Int$7000; by 2008, the relationship resembled an inverted U for women, peaking at middle-income levels. BMI had a positive relationship with the percentage of urban population in both 1980 and 2008. Fasting plasma glucose had weaker associations with these country macro characteristics, but it was positively associated with BMI. Conclusions— The changing associations of metabolic risk factors with macroeconomic variables indicate that there will be a global pandemic of hyperglycemia and diabetes mellitus, together with high blood pressure in low-income countries, unless effective lifestyle and pharmacological interventions are implemented.
Published: 2013

7. Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours

Author: PARATI, GIANFRANCO, BILO, GRZEGORZ, MANCIA, GIUSEPPE, Omboni, S, Palatini, P, Rizzoni, D, Valentini, M, Agabiti Rosei, E, on behalf of the Italian Society of Hypertension Working Group on Blood Pressure Monitoring, Parati, G, Omboni, S, Palatini, P, Rizzoni, D, Bilo, G, Valentini, M, Agabiti Rosei, E, Mancia, G, and on behalf of the Italian Society of Hypertension Working Group on Blood Pressure, M
Subjects: medicine.medical_specialty, Special populations, Ambulatory blood pressure, business.industry, MEDLINE, medicine.disease, guidelines, italian society of hypertension, Blood pressure, Ambulatory, Internal Medicine, medicine, Blood pressure monitoring, Medical emergency, Data reporting, Cardiology and Cardiovascular Medicine, Intensive care medicine, business, Patient education
Abstract: This article offers instructions and recommendations on how to perform blood pressure measurements in the doctor's office, in the patient's home and in ambulatory conditions over 24 hours. Great attention is paid to some of the general aspects of blood pressure measurement, including the accuracy of blood pressure measuring devices, the importance of a 'white coat effect', and the need for patient education. This article also deals with a number of practical details, such as the importance of patient's relaxation and position, arm position and support, arm selection and cuff selection and application. Recommendations are provided on the observer's position and performance, and on the need to pay attention to specific factors affecting the blood pressure measurement in different patient populations, namely in children, elderly and obese people, pregnant women, patients with arrhythmias and patients on treatment. This article then separately focuses on the characteristics of auscultatory and automated measurements, the latter performed either in the office, at home or over 24 hours in ambulatory settings. Home blood pressure monitoring (HBPM) is becoming increasingly important in the diagnosis and management of arterial hypertension. The importance of HBPM in cardiovascular prevention, related to a deeper involvement of patients in their long-term management, and the wide diffusion of this approach in populations, is not always accompanied by adequate knowledge of how to make proper use of this technique, which emphasizes the need for more precise recommendations. This article summarizes the available evidence and provides recommendations on the use of home blood pressure monitoring in clinical practice and in research. It updates the previous recommendations on the same topic issued in 2000. The main topics addressed include the methodology of HBPM, focusing on measurement conditions and procedures, ranging from patient/subject position, to arm selection, arm position and support, cuff selection and application and data reporting, diagnostic and therapeutic thresholds, clinical applications in hypertension (with specific reference to special populations) and its applications in research. Special attention is given to device validation and selection as well as to patient education and to the need of HBPM to be guided by the physician in charge. The final section deals with the problems related to the implementation of these recommendations in clinical practice. Finally, the methodology and clinical impact of 24-hour ambulatory blood pressure monitoring are also addressed in detail, focusing on the parameters that can be derived from the analysis of 24-hour blood pressure recordings applied both to the diagnostic and prognostic evaluation of hypertensive patients and to the assessment of the effectiveness of antihypertensive treatment in controlling blood pressure through the day and night. Instructions to users on how to properly perform HBPM are provided as an appendix. © 2008 Adis Data Information BV. All rights reserved.
Published: 2008

8. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma

Author: Rossi, Gp, Belfiore, A, Bernini, Giampaolo, Desideri, G, Fabris, B, Ferri, C, Giacchetti, G, Letizia, C, Maccario, M, Mallamaci, F, Mannelli, M, Palombo, G, Rizzoni, D, Rossi, E, AGABITI ROSEI, E, Pessina, Ac, Mantero, F, FOR THE PAPY STUDY INVESTIGATORS, Rossi, G. P., Belfiore, A., Bernini, G., Desideri, G., Fabris, Bruno, Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mallamaci, F., Mannelli, M., Palumbo, G., Rizzoni, D., Rossi, E., Agabiti Rosei, E., Pessina, A. C., Mantero, F., and Primary Aldosteronism Prevalence In Italy Study, Investigators
Subjects: Male, Captopril, diagnosis, secondary hypertension, aldosterone, aldosteronism, clinical science, secondary, Secondary hypertension, Primary hyperaldosteronism, multiple tests, Sodium Chloride, chemistry.chemical_compound, Primary aldosteronism, Analysis of Variance Captopril/diagnostic use, Prospective Studies, Infusions, Intravenous, Aldosterone, Adrenocortical Adenoma, Captopril challenge test, Female, Intravenous, Adrenocortical Adenoma/diagnosis, medicine.drug, Infusions, medicine.medical_specialty, Adenoma, medicine.drug_class, Urology, Sensitivity and Specificity, Diagnosis, Differential, Internal medicine, Hyperaldosteronism, Adrenal Cortex Neoplasms/diagnosis, Diagnosis, Differential, Hyperaldosteronism/diagnosis, Probability, Sodium Chloride/diagnostic use, Internal Medicine, medicine, Humans, Analysis of Variance, business.industry, medicine.disease, Adrenal Cortex Neoplasms, Endocrinology, chemistry, Mineralocorticoid, ACE inhibitor, business
Abstract: We performed a prospective head-to-head comparison of the accuracy of the captopril test (CAPT) and the saline infusion test (SAL) for confirming primary aldosteronism due to an aldosterone-producing adenoma (APA) in patients with different sodium intake. A total of 317 (26.9%) of the 1125 patients screened in the Primary Aldosteronism Prevalence in Italy Study underwent both CAPT and SAL. They were composed of the patients with a high aldosterone/renin ratio baseline and 1 every 4 patients without such criterion. The accuracy of post-CAPT or post-SAL plasma aldosterone values for diagnosing APA was estimated with the area under the receiver operator characteristics curves. Primary aldosteronism was found in 120 patients, of which 46 had an APA. No untoward effect occurred with either test. The area under the receiver operator characteristics curve of plasma aldosterone for both tests was higher ( P P =0.054). The optimal aldosterone cutoff value for identifying APA was 13.9 and 6.75 ng/dL for the CAPT and SAL, respectively. Even at these cutoffs, sensitivity and specificity were moderate because of overlap of values between patients with and without APA. When examined in relation to sodium intake, the accuracy of the SAL surpassed that of the CAPT in the patients with a sodium intake ≤130 mEq per day; this difference waned at a higher Na + intake. Thus, both the CAPT and the SAL are safe and moderately accurate for excluding APA; at a sodium intake >7.6 g per day, the SAL offers no advantage over the easier-to-perform CAPT.
Published: 2007

9. 2007 Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author: MANCIA, GIUSEPPE, GRASSI, GUIDO, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Heagerty, AM, Kjeldsen, SE, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, RE, Struijker Boudier, HAJ, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, SD, McGregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, JL, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, LH, Mancia, G, Manolis, A, Nilsson, PM, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, Manolis, AJ, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, n, The task force for the management of arterial hypertension of the European Society of Cardiology, n., University of Zurich, Mancia, G, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, A, Kjeldsen, S, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, R, Struijker Boudier, H, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, S, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, J, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, L, Manolis, A, Nilsson, P, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, N, and The task force for the management of arterial hypertension of the European Society of Cardiology, N
Subjects: Pediatrics, medicine.medical_specialty, business.industry, Alternative medicine, 610 Medicine & health, World health, 2705 Cardiology and Cardiovascular Medicine, Organ damage, Europe, Resource (project management), Family medicine, Medical, Health care, Hypertension, medicine, 10209 Clinic for Cardiology, Diagnostic assessment, Humans, Cardiology and Cardiovascular Medicine, business, Hypertension/classification/diagnosis/therapy, Societies, Societies, Medical, Medical literature
Abstract: For several years the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) decided not to produce their own guidelines on the diagnosis and treatment of hypertension but to endorse the guidelines on hypertension issued by the World Health Organization (WHO) and International Society of Hypertension (ISH)1,2 with some adaptation to reflect the situation in Europe. However, in 2003 the decision was taken to publish ESH/ESC specific guidelines3 based on the fact that, because the WHO/ISH Guidelines address countries widely varying in the extent of their health care and availability of economic resource, they contain diagnostic and therapeutic recommendations that may be not totally appropriate for European countries. In Europe care provisions may often allow a more in-depth diagnostic assessment of cardiovascular risk and organ damage of hypertensive individuals as well as a wider choice of antihypertensive treatment. The 2003 ESH/ESC Guidelines3 were well received by the clinical world and have been the most widely quoted paper in the medical literature in the last two years.4 However, since 2003 considerable additional evidence on important issues related to diagnostic and treatment approaches to hypertension has become available and therefore updating of the previous guidelines has been found advisable. In preparing the new guidelines the Committee established by the ESH and ESC has agreed to adhere to the principles informing the 2003 Guidelines, namely 1) to try to offer the best available and most balanced recommendation to all health care providers involved in the management of hypertension, 2) to address this aim again by an extensive and critical review of the data accompanied by a series of boxes where specific recommendations are given, as well as by a concise set of practice recommendations to be published soon thereafter as already done in 2003; …
Published: 2007

10. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma

Author: Rossi, Gp, Belfiore, A, Bernini, G, Desideri, Giovambattista, Fabris, B, Ferri, Claudio, Giacchetti, G, Letizia, C, Maccario, M, Mallamaci, F, Mannelli, M, Montemurro, D, Palumbo, G, Rizzoni, D, Rossi, E, Semplicini, A, AGABITI ROSEI, E, Pessina, Ac, Mantero, F, Papy, Study, Investigators, Rossi, Gp, Belfiore, A, Bernini, G, Desideri, G, Fabris, Bruno, Ferri, C, Giacchetti, G, Letizia, C, Maccario, M, Mallamaci, F, Mannelli, M, Montemurro, D, Palumbo, G, Rizzoni, D, Rossi, E, Semplicini, A, AGABITI ROSEI, E, Pessina, Ac, and Mantero, F.
Subjects: Adenoma, medicine.medical_specialty, Hydrocortisone, Physiology, medicine.drug_class, Urology, Adrenal Gland Neoplasms, Secondary hypertension, Sodium Chloride, Diagnosis, Differential, chemistry.chemical_compound, Primary aldosteronism, Internal medicine, Hyperaldosteronism, Renin, Internal Medicine, Medicine, Humans, Prospective Studies, Prospective cohort study, Infusions, Intravenous, Aldosterone, Aldosteronism, business.industry, Reproducibility of Results, Middle Aged, medicine.disease, Endocrinology, chemistry, ROC Curve, Mineralocorticoid, Hypertension, Differential diagnosis, Cardiology and Cardiovascular Medicine, business
Abstract: BACKGROUND: Data on the performance of the tests used to confirm the diagnosis of primary aldosteronism (PA) are limited. OBJECTIVE: To prospectively investigate the accuracy of the saline infusion test (SIT). METHODS: Three hundred and seventeen (26.9%) out of 1125 patients screened in the PAPY study underwent measurement of plasma aldosterone, cortisol and renin activity after infusion of 2 l of isotonic saline intravenously over 4 h. They comprised patients with a baseline aldosterone/renin ratio (ARR) > 40 and one every four patients not fulfilling such criterion. The area under the receiver-operator characteristic curves (AUC) of aldosterone values after SIT was used as a measure of accuracy for diagnosing PA, aldosterone-producing adenoma (APA) or idiopathic hyperaldosteronism (IHA). RESULTS: One hundred and twenty (37.9%) patients had PA that was due to an APA in 46 (38.3%) and to IHA in 74 (61.7%). No untoward effect occurred with the SIT. The AUC (0.811 ± 0.026, 0.878 ± 0.040 and 0.784 ± 0.034 for identification of PA, APA and IHA, respectively) was higher (P < 0.0001) than that under the diagonal. By sensitivity/specificity versus criterion values plot, the best aldosterone cut-off values for identifying APA and IHA were 6.75 and 6.91 ng/dl, respectively. However, even at these optimal cut-offs, sensitivity and specificity were moderate because of values overlapping between patients with and without the disease. Moreover, there were no differences of AUC and aldosterone cut-offs between APA and IHA. CONCLUSION: In a multicenter study the SIT was safe and specific for excluding PA, but had no place for discriminating between an APA and IHA.
Published: 2007

11. [OP.1B.09] RELATIONSHIP BETWEEN CHA2DS2-VASC SCORE AND PRECLINICAL CARDIOVASCULAR ORGAN DAMAGE IN A GENERAL POPULATION IN NORTHERN ITALY

Author: Agabiti Rosei E, G. Rubagotti, Agabiti Rosei C, Anna Paini, Carlo Aggiusti, M. Salvetti, G. Maruelli, Fabio Bertacchini, and M.L. Muiesan
Subjects: medicine.medical_specialty, education.field_of_study, Physiology, business.industry, Population, Northern italy, Surgery, Organ damage, Internal medicine, CHA2DS2–VASc score, Internal Medicine, Medicine, Cardiology and Cardiovascular Medicine, business, education
Published: 2016

12. [OP.7A.01] OBESITY, INCIDENT CARDIOVASCULAR EVENTS AND ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY. THE MOLI-SANI STUDY

Author: de Gaetano G, Martino Vaglio, Licia Iacoviello, Maria Benedetta Donati, Simona Costanzo, Di Castelnuovo A, Anna Paini, Assanelli A, M. Salvetti, M.L. Muiesan, Fabio Badilini, and Agabiti Rosei E
Subjects: medicine.medical_specialty, Physiology, business.industry, Internal medicine, Internal Medicine, medicine, Cardiology, Cardiology and Cardiovascular Medicine, business, medicine.disease, Left ventricular hypertrophy, Obesity
Published: 2016

13. Arterial spontaneous rhythmic contractile activity in humans and rats: spectral analysis and regulatory mechanisms

Author: Paolo Muiesan, Angelo Cinelli, Enzo Porteri, Agabiti Rosei E, Giorgio Bettoni, M.L. Muiesan, Stefano Maria Giulini, Damiano Rizzoni, Massimo Salvetti, and M. Castellano
Subjects: Adult, Male, Sympathetic nervous system, medicine.medical_specialty, Physiology, Blood Pressure, Autonomic Nervous System, Rats, Inbred WKY, Nitric oxide, Norepinephrine, chemistry.chemical_compound, Heart Rate, Rats, Inbred SHR, Internal medicine, Internal Medicine, medicine, Animals, Humans, Sympathomimetics, Mesenteric arteries, Vasomotor, business.industry, Spectrum Analysis, Arteries, Middle Aged, Acetylcholine, Rats, Vasomotor System, Autonomic nervous system, medicine.anatomical_structure, Blood pressure, Endocrinology, chemistry, Anesthesia, Hypertension, Female, Cardiology and Cardiovascular Medicine, business, Artery, medicine.drug
Abstract: Objective: Many experimental observations have demonstrated the presence of spontaneous cyclic vasomotor activity (CVA) in large and small arteries. This study aimed to evaluate the characteristics of spontaneous CVA in rat and human resistance arteries, and to investigate its possible interference with the evaluation of sympathetic activity by means of spectral analysis of blood pressure in vivo. Design and results: In study 1 we examined small mesenteric arteries of spontaneously hypertensive rats and Wistar-Kyoto rats, as well as small omental arteries of normotensive subjects and hypertensive patients (Mulvany and Halpern technique). CVA was enhanced by the agonists of nitric oxide release, and was abolished by the inhibitors of nitric oxide or cyclic GMP synthesis. A potassium channel, which is barium- and zinc-sensitive and tetraethylammonium-insensitive, seems to play a crucial role in the genesis of CVA. In rats and in humans the frequency of CVA fell exactly in the frequency band ('low frequencies') of power spectral analysis of blood pressure usually considered to be an 'index of sympathetic activity'. In study 2, a power spectral analysis of blood pressure variability before and after intra-arterial infusion of noradrenaline or acetylcholine was performed in 18 patients with mild-to-moderate hypertension. The absolute and normalized spectral power of the low-frequency systolic blood pressure peak increased remarkably after noradrenaline and acetylcholine infusion, while its central frequency shifted from 0.10 Hz to approximately 0.06 Hz, exactly the frequency of CVA observed in vitro. Conclusions: A potassium channel appears to be involved in the genesis of CVA. Also, CVA might contribute to the blood pressure variability independently of the autonomic nervous system activity, and thus probably plays a role in the genesis of the low-frequency peak in the rat and in humans.
Published: 1995

14. Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study

Author: Lonati, C, Morganti, A, Comarella, L, Mancia, G, Zanchetti, A, IPERDIA STUDY GROUP (ABATE, G, AGABITI ROSEI, E, Ambrosio, Gb, Ambrosioni, E, Bellini, G, Cavatorta, A, Cerasola, G, Cereda, Ug, DE DIVITIIS, O, Ferrari, A, Lechi, A, Leonetti, G, Martines, C, Nami, R, Pagani, M, Palatini, P, Pasotti, C, Pirrelli, A, Portaluppi, F, Rappelli, A, Salvetti, A, Santucci, A, Vanuzzo, D, Veglio, Franco, Venco, A, Volpe, M., LONATI C, MORGANTI A, COMARELLA L, MANCIA G, ZANCHETTI A, CERASOLA G, and THE IPERDIA STUDY GROUP
Subjects: Blood Glucose, Male, medicine.medical_specialty, hypertension, Physiology, Blood Pressure, diabetes, prevalence, Type 2 diabetes, Ambulatory Care Facilities, Cohort Studies, chemistry.chemical_compound, Risk Factors, Internal medicine, Diabetes mellitus, Prevalence, Internal Medicine, medicine, Humans, Outpatient clinic, Aged, Creatinine, Glucose tolerance test, Diabete di tipo 2, ipertensione arteriosa, medicine.diagnostic_test, business.industry, Glucose Tolerance Test, Middle Aged, medicine.disease, Blood pressure, Endocrinology, Diabetes Mellitus, Type 2, Italy, chemistry, Female, Microalbuminuria, Cardiology and Cardiovascular Medicine, business, Cohort study
Abstract: BACKGROUND AND PURPOSE Hypertension is known to be highly prevalent among patients with diabetes and associated with an increased risk of cardiovascular damage. In contrast, relatively few investigations have addressed the prevalence of diabetes among patients with hypertension. The purpose of the present study was to examine the prevalence of type 2 diabetes, the effectiveness of hypertension and diabetes control and the association with other cardiovascular risk factors and previous cardiovascular diseases in a cohort of patients with hypertension referred to 30 hospital outpatient clinics for the treatment of hypertension. METHODS AND PATIENTS Patients were considered as having diabetes if they were already on an antidiabetic treatment either with diet or medications. All other patients had fasting plasma glucose measured on two separate occasions and were classified as having diabetes if both values were at least 140 mg/dl (7.8 mmol/l) and as not having diabetes if both values were less than 110 mg/dl (6.1 mmol/l). In patients with a single determination of at least 110 mg/dl, the final diagnosis of diabetes was established according to the result of an oral glucose tolerance test. A secondary definition of diabetes was also used, that is two fasting plasma glucose values of at least 126 mg/dl (7.0 mmol/l). In all patients, serum total, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, fasting serum triglycerides, serum creatinine and urinary albumin were also evaluated. RESULTS AND CONCLUSION Among the 1397 recruited patients, 242 (17.3%) were diagnosed as having diabetes according to the primary definition and 244 (17.5%) according to the secondary definition. In 195 out of the 242 (14%), the diagnosis was already known whereas, in the remaining 47 (3.3%), it was made de novo. In 61.4% of those already having diabetes, plasma glucose was at least 140 mg/dl (7.8 mmol/l), whereas only in 8.4% of them was it less than 110 mg/dl (6.1 mmol/l). Patients with diabetes were older, heavier and with a greater familiar predisposition. Patients with diabetes had higher values of systolic blood pressure than individuals without diabetes (150 +/- 17 vs. 144 +/- 16 mmHg, respectively; P < 0.001), lower high-density lipoprotein cholesterol and higher triglycerides and microalbuminuria. Overall, among patients with hypertension and diabetes, only 3% had blood pressure and HbA1c within the recommended limits. The prevalence of previous cardiovascular disorders was two to three times higher than among individuals without diabetes.
Published: 2008

15. Acute and Chronic Effects of Nifedipine on Plasma Renin Activity and Plasma Adrenaline and Noradrenaline in Controls and Hypertensive Patients

Author: G. Muiesan, Luigi Corea, Agabiti-Rosei E, E. Boschetti, Miele N, and Maurizio Bentivoglio
Subjects: Adult, Male, medicine.medical_specialty, Epinephrine, Nifedipine, Pyridines, medicine.drug_class, Blood Pressure, Essential hypertension, Plasma renin activity, Sublingual administration, Norepinephrine, Heart Rate, Reference Values, Internal medicine, Renin, Heart rate, medicine, Humans, Antihypertensive drug, business.industry, Antagonist, General Medicine, Middle Aged, medicine.disease, Endocrinology, Blood pressure, Hypertension, Female, business, medicine.drug
Abstract: 1. Nifedipine, a calcium antagonist drug, was given sublingually (10 mg) to seven normal subjects and 19 patients with essential hypertension. In addition, 12 of the hypertensive subjects then received nifedipine (10 mg thrice daily) for 3 weeks. 2. Sublingual administration of nifedipine in hypertensive patients induced a prompt and sustained reduction of blood pressure, without a significant increase of heart rate; in normotensive subjects blood pressure did not change, and heart rate was significantly increased. After chronic treatment, blood pressure remained reduced and heart rate did not rise. 3. Plasma catecholamines and plasma renin activity increased significantly in normotensive subjects after acute administration. 4. After both acute and chronic administration, only plasma noradrenaline was significantly increased in hypertensive patients; in long-term treatment, it was increased in both the lying and standing positions. 5. Nifedipine is an active antihypertensive drug, which may induce some degree of sympathetic activation.
Published: 1979

16. Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy

Author: Claudio Mencacci, Alberico L. Catapano, Roberto Trevisan, Giorgio L Colombo, Alberto Margonato, Carlomaurizio Montecucco, Enrico Agabiti-Rosei, Colombo, G, Agabiti-Rosei, E, Margonato, A, Mencacci, C, Montecucco, C, Trevisan, R, Catapano, A, Colombo, G. L., Agabiti Rosei, E, Margonato, Alberto, Montecucco C., M, and Catapano, A. L.
Subjects: Male, Pediatrics, medicine.medical_specialty, Health Knowledge, Attitudes, Practice, Time Factors, Databases, Factual, Population, Comorbidity, 030204 cardiovascular system & hematology, Drug Substitution, Drug Prescriptions, Medication Adherence, 03 medical and health sciences, Insurance Claim Review, 0302 clinical medicine, Internal medicine, Generic drug, Health care, medicine, Internal Medicine, Drugs, Generic, Humans, 030212 general & internal medicine, Medical prescription, education, Aged, Retrospective Studies, Polypharmacy, Aged, 80 and over, education.field_of_study, business.industry, Age Factors, Drugs, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Administrative databases, Italy, Adherence, Female, business, Cardiology and Cardiovascular Medicine, Administrative Claims, Healthcare, Compliance, Adherence, Administrative databases, Compliance, Drugs
Abstract: Background The use of generics, equivalent but less expensive drugs, is an important opportunity to reduce healthcare expenditure. Methods The purpose of this study was to investigate the effect of substitution between unbranded generics on persistence and adherence to therapy in two Italian Local Health Units (ASL) in real-world clinical practice in 5 therapeutic areas using tracing drugs. Substitution of generic drugs is any change in the name of the manufacturer of the generic drug. The therapeutic areas were: diabetes (metformin); hypertension (amlodipine); dyslipidemia (simvastatin); psychiatry (sertraline); cardiology (propafenone); osteoporosis (alendronate). The retrospective analysis was carried out on the administrative databases of two Local Healthcare Units (ASL – Azienda sanitaria locale Bergamo (BG) and Pavia (PV)) in the Lombardy Region of Italy. The correlation between persistence and adherence with the different cohorts of generic substitution frequency within each therapeutic area was then calculated. Results According to the inclusion criteria, 23,773 patients were evaluated. Patients were observed for a period of 36 months starting from the first drug delivery (index date). The median age of the overall population was above 61 years in all therapeutic areas. The generic drug substitution occurred in 61.5% of patients (BG: 57.6% and PV: 65.4% respectively); Hypertension was the therapeutic area with the highest percentage of patients with substitutions. Patients' adherence, evaluated by the Medical Possession Rate (MPR) and persistence to the treatment decreases with the increase in the frequency of generic substitutions. This observation was confirmed by a statistically significant negative correlation (p-value of
Published: 2016

17. Echocardiography in clinical practice: the burden of arterial hypertension. A multicenter Italian survey

Author: Francesca Negri, Alberto Morganti, Enrico Agabiti-Rosei, G. De Simone, Giuliano Tocci, Cesare Cuspidi, Valentina Giudici, N. De Luca, M.L. Muiesan, Anna Capra, Cuspidi, C, Negri, F, Giudici, V, Capra, A, Muiesan, M, Agabiti rosei, E, De Simone, G, De Luca, N, Tocci, G, Morganti, A, Muiesan, Ml, Agabiti Rosei, E, DE SIMONE, Giovanni, DE LUCA, Nicola, and Morganti, A.
Subjects: Adult, Male, medicine.medical_specialty, Heart Valve Diseases, Myocardial Ischemia, Left ventricular hypertrophy, Body Mass Index, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Prevalence, Humans, LV hypertrophy, echocardiography, burden of arterial hypertension, Aged, Body surface area, Heart Failure, business.industry, Echo (computing), Smoking, Arrhythmias, Cardiac, Middle Aged, medicine.disease, Clinical Practice, Diabetes Mellitus, Type 2, Italy, Echocardiography, Hypertension, Cardiology, Female, Hypertrophy, Left Ventricular, business, Wall thickness, Body mass index
Abstract: Little information is available about the burden of hypertension on echo-lab activity in current practice. The aim of the present nation-wide survey in outpatient echo-labs was to investigate the prevalence rates of (1) echo examinations performed for the evaluation of hypertensive cardiac damage; (2) reports providing quantitative data on left ventricular (LV) structure and geometry; (3) LV hypertrophy (LVH) in hypertensives referred to echo labs. The study was carried out in 14 outpatient echo-labs across Italy. Prescriptions written by general practitioners were used to identify the indications for the examinations. Estimates of LVH were derived from original echo reports or were calculated from LV primary measures, when available, with Devereux's formula in a post-analysis. Echo examination was performed in 2449 subjects (1245 men and 1204 women); hypertension was the indication for echo in 745 (30.4%) cases. In this subgroup, LV mass (LVM), LVM indexed to body surface area, LVM indexed to height 2.7 and relative wall thickness ratio were reported in 58, 59, 54 and 52%, respectively. LVH was present in 53% of untreated hypertensives and, among treated patients, in 45 and 65% of those with and without blood pressure control, respectively. Our findings show that (1) hypertension accounts for approximately one-third of echo examinations performed in clinical practice; (2) a large fraction of echo reports do not provide quantitative data on LVM and LV geometry, (3) LVH is highly prevalent in hypertensives referred to echo labs for assessment of cardiac damage. © 2010 Macmillan Publishers Limited All rights reserved.
Published: 2009

18. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

Author: Giuseppe Mancia, Enrico Agabiti-Rosei, Josep Redon, Richard J. Johnson, E. Lurbe, Austin G. Stack, Konstantinos Tsioufis, Claudio Borghi, Jan T. Kielstein, and Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP
Subjects: medicine.medical_specialty, Gout, Heart disease, Allopurinol, Hyperuricemia, Type 2 diabetes, 030204 cardiovascular system & hematology, urologic and male genital diseases, Coronary artery disease, 03 medical and health sciences, chemistry.chemical_compound, Febuxostat, 0302 clinical medicine, Internal medicine, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Metabolic Syndrome, business.industry, nutritional and metabolic diseases, medicine.disease, Uric Acid, Diabetes Mellitus, Type 2, chemistry, Hypertension, Cardiology, Uric acid, Metabolic syndrome, business, Hyperuricaemia, Kidney disease, medicine.drug
Abstract: During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes. Here we review the connection between hyperuricaemia and cardiovascular, kidney and metabolic diseases. Contrary to the popular view that uric acid is an inert metabolite of purine metabolism, recent studies suggest serum uric acid may have a variety of pro-inflammatory, pro-oxidative and vasoconstrictive actions that may contribute to cardiometabolic diseases. Hyperuricaemia is a predictive factor for the development of hypertension, metabolic syndrome, type 2 diabetes, coronary artery disease, left ventricular hypertrophy, atrial fibrillation, myocardial infarction, stroke, heart failure and chronic kidney disease. Treatment with uric acid-lowering therapies has also been found to improve outcomes in patients with hypertension and kidney disease, in some but not all studies. In conclusion, uric acid is emerging as a potentially treatable risk factor for cardiometabolic diseases, and more clinical trials investigating the potential benefit of lowering serum uric acid are recommended in individuals with hyperuricaemia with and without deposition and concomitant hypertension, metabolic syndrome or chronic kidney disease.
Published: 2020

19. Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases. A Consensus Document by the Italian Society of Hypertension (SIIA)

Author: Del Pinto Rita, Grassi, Guido, Ferri, Claudio, Pengo Martino, F, Lombardi, Carolina, Pucci, Giacomo, Salvetti, Massimo, Parati, Gianfranco, Italian Society of Hypertension (SIIA), Muiesan Maria Lorenza, Sechi, Leonardo, Cicero Arrigo FG, Iaccarino, Guido, Minuz, Pietro, Mulatero, Paolo, Mulè, Giuseppe, Savoia, Carmine, Borghi, Claudio, Volpe, Massimo, Agabiti Rosei Enrico, Cipollone, Francesco, Desideri, Giovambattista, Virdis, Agostino., Del Pinto R, Grassi G, Ferri C, Pengo MF, Lombardi C, Pucci G, Salvetti M, Parati G, Italian Society of Hypertension (SIIA), SIIA Young Researchers Study Group, President of SIIA, Past President of SIIA, Cicero AFG, Borghi C, Del Pinto R., Grassi G., Ferri C., Pengo M.F., Lombardi C., Pucci G., Salvetti M., Parati G., DelPinto R., Muiesan M.L., Sechi L., Cicero A.F.G., Iaccarino G., Minuz P., Mulatero P., Mule' G., Savoia C., Borghi C., Volpe M., Agabiti Rosei E., Cipollone F., Desideri G., Virdis A., Del Pinto, R, Grassi, G, Ferri, C, Pengo, M, Lombardi, C, Pucci, G, Salvetti, M, Parati, G, Rita, Del Pinto, Guido, Grassi, Claudio, Ferri, Martino F, Pengo, Carolina, Lombardi, Giacomo, Pucci, Massimo, Salvetti, Gianfranco, Parati, and Iaccarino, Guido
Subjects: 0301 basic medicine, medicine.medical_treatment, Sleep disorders, Comorbidity, 0302 clinical medicine, Cardiovascular Disease, Sleep Initiation and Maintenance Disorders, Insomnia, Continuous positive airway pressure, Sleep Apnea, Obstructive, Continuous Positive Airway Pressure, blood pressure, Heart Disease Risk Factor, Prognosis, Sleep in non-human animals, Circadian Rhythm, Antihypertensive Agent, Cardiovascular Diseases, sleep disorders, medicine.symptom, Cardiology and Cardiovascular Medicine, Risk assessment, Human, cardiovascular risk, medicine.medical_specialty, Consensus, Sleep Apnea, hypertension, Prognosi, Consensu, Risk Assessment, 03 medical and health sciences, Therapeutic approach, Internal Medicine, medicine, Humans, Healthy Lifestyle, Intensive care medicine, Consensus Document, Antihypertensive Agents, Blood pressure, Cardiovascular risk, Hypertension, Blood Pressure, Heart Disease Risk Factors, Risk Reduction Behavior, Sleep, Sleep disorder, business.industry, Obstructive, Public health, medicine.disease, 030104 developmental biology, business, 030217 neurology & neurosurgery
Abstract: Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate management of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, sleep disturbances are often unrecognized, or heterogeneity exists in their management by non-specialists in the field. This document by the Italian Society of Hypertension summarizes the updated evidence linking sleep disorders to hypertension and cardiovascular diseases, the major underlying mechanisms, and the possible management strategies. A simplified, evidence-based diagnostic and therapeutic algorithm for comorbid hypertension and common sleep disorders, namely obstructive sleep apnoea and insomnia, is proposed.
Published: 2021

20. Isolated systolic hypertension in the young

Author: Giuseppe Mancia, Carmel M. McEniery, Stevo Julius, Francesca Saladini, Alberto Zanchetti, Pasquale Strazzullo, Ian B. Wilkinson, Bojan Jelakovich, Gianfranco Parati, Cristina Giannattasio, Michael F. O'Rourke, Paolo Palatini, Konstantinos Tsioufis, G. Bilo, Paolo Pauletto, Alberto Avolio, Guido Grassi, Enrico Agabiti Rosei, Giacomo Pucci, Lorenzo Ghiadoni, Edoardo Casiglia, Palatini, Paolo, Rosei, Enrico Agabiti, Avolio, Alberto, Bilo, Gregorz, Casiglia, Edoardo, Ghiadoni, Lorenzo, Giannattasio, Cristina, Grassi, Guido, Jelakovich, Bojan, Julius, Stevo, Mancia, Giuseppe, Mceniery, Carmel M., O'Rourke, Michael F., Parati, Gianfranco, Pauletto, Paolo, Pucci, Giacomo, Saladini, Francesca, Strazzullo, Pasquale, Tsioufis, Konstantino, Wilkinson, Ian B., Zanchetti, Alberto, Palatini, P, Agabiti Rosei, E, Avolio, A, Bilo, G, Casiglia, E, Ghiadoni, L, Giannattasio, C, Grassi, G, Jelakovich, B, Julius, S, Mancia, G, Mceniery, C, O’Rourke, M, Parati, G, Pauletto, P, Pucci, G, Saladini, F, Strazzullo, P, Tsioufis, K, Wilkinson, I, Zanchetti, A, McEniery, Carmel [0000-0003-3636-0705], Wilkinson, Ian [0000-0001-6598-9399], and Apollo - University of Cambridge Repository
Subjects: arterial stiffness, central blood pressure, stroke volume, systolic hypertension, young, Internal Medicine, Physiology, Cardiology and Cardiovascular Medicine, Systolic hypertension, Blood Pressure, White coat hypertension, 030204 cardiovascular system & hematology, 0302 clinical medicine, Risk Factors, arterial stiffne, Prevalence, 030212 general & internal medicine, Young adult, Child, Pulse wave velocity, Societies, Medical, Stroke volume, Middle Aged, Prognosis, Europe, Hypertension, Practice Guidelines as Topic, White Coat Hypertension, Adult, medicine.medical_specialty, Adolescent, Pulse Wave Analysis, Young Adult, 03 medical and health sciences, Medical, medicine, Humans, Obesity, Intensive care medicine, Life Style, Antihypertensive Agents, business.industry, Blood Pressure Determination, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, Clinical trial, Blood pressure, systolic hypertension, young, Societies, business
Abstract: Whether isolated systolic hypertension in the young (ISHY) implies a worse outcome and needs antihypertensive treatment is still a matter for dispute. ISHY is thought to have different mechanisms than systolic hypertension in the elderly. However, findings from previous studies have provided inconsistent results. From the analysis of the literature, two main lines of research and conceptualization have emerged. Simultaneous assessment of peripheral and central blood pressure led to the identification of a condition called pseudo or spurious hypertension, which was considered an innocent condition. However, an increase in pulse wave velocity has been found by some authors in about 20% of the individuals with ISHY. In addition, obesity and metabolic disturbances have often been documented to be associated with ISHY both in children and young adults. The first aspect to consider whenever evaluating a person with ISHY is the possible presence of white-coat hypertension, which has been frequently found in this condition. In addition, assessment of central blood pressure is useful for identifying ISHY patients whose central blood pressure is normal. ISHY is infrequently mentioned in the guidelines on diagnosis and treatment of hypertension. According to the 2013 European Guidelines on the management of hypertension, people with ISHY should be followed carefully, modifying risk factors by lifestyle changes and avoiding antihypertensive drugs. Only future clinical trials will elucidate if a benefit can be achieved with pharmacological treatment in some subgroups of ISHY patients with associated risk factors and/or high central blood pressure.
Published: 2018

21. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol

Author: George L. Bakris, Moo Yong Rhee, Richard J McManus, Konstantinos Tsioufis, Kushal Madan, Juan Eugenio Ochoa, Franco Cecchi, Paolo Palatini, Enrico Agabiti-Rosei, Davide Soranna, Paulina Wijnmaalen, Josep Redon, Alberto Zanchetti, Antonella Zambon, Roland E. Schmieder, Pietro Amedeo Modesti, Thomas Kahan, Sabine Perl, Alejandro de la Sierra, Maria Dorobantu, Thays Faria, Mónica Doménech, Bojan Jelaković, Giuseppe Mancia, Jeong Bae Park, Franco Veglio, Ramiro A. Sanchez, Gabriel Waisman, Enrique Rodilla Sala, Giovanna Branzi, Stefano Omboni, Dario Pellegrini, Alexandra Konradi, Yuqing Zhang, Maria Grazia Valsecchi, Nanfang Li, Yong Huo, Ji-Guang Wang, Marzena Chrostowska, Cristian Podoleanu, Nicolas Federico Renna, Stéphane Laurent, Gianfranco Parati, Giacomo Pucci, Milos Stojanovic, José A. Octavio, George S. Stergiou, Grzegorz Bilo, UCH. Departamento de Medicina (Extinguido), Producción Científica UCH 2018, UCH. Departamento de Medicina y Cirugía, Parati, G, Agabiti-Rosei, E, Bakris, G, Bilo, G, Branzi, G, Cecchi, F, Chrostowska, M, De la Sierra, A, Domenech, M, Dorobantu, M, Faria, T, Huo, Y, Jelaković, B, Kahan, T, Konradi, A, Laurent, S, Li, N, Madan, K, Mancia, G, Mcmanus, R, Modesti, P, Ochoa, J, Octavio, J, Omboni, S, Palatini, P, Park, J, Pellegrini, D, Perl, S, Podoleanu, C, Pucci, G, Redon, J, Renna, N, Rhee, M, Rodilla Sala, E, Sanchez, R, Schmieder, R, Soranna, D, Stergiou, G, Stojanovic, M, Tsioufis, K, Valsecchi, M, Veglio, F, Waisman, G, Wang, J, Wijnmaalen, P, Zambon, A, Zanchetti, A, and Zhang, Y
Subjects: HYPERTENSION MANAGEMENT, Hipertensión, masked uncontrolled hypertension, Enfermedades cardiovasculares - Pacientes - Factores de riesgo, office blood pressure, MASKED UNCONTROLLED HYPERTENSION, Medicina Clínica, Cardiovascular Medicine, 030204 cardiovascular system & hematology, AMBULATORY BLOOD PRESSURE MONITORING, law.invention, 0302 clinical medicine, Clinical trials, Randomized controlled trial, law, Blood Pressure Monitoring, Masked Hypertension, purl.org/becyt/ford/3.2 [https], Protocol, Multicenter Studies as Topic, 030212 general & internal medicine, Cardiovascular system - Diseases - Patients - Risk factors, Blood pressure, OFFICE BLOOD PRESSURE, Randomized Controlled Trials as Topic, Sistemas Cardíaco y Cardiovascular, General Medicine, Blood Pressure Monitoring, Ambulatory, 3. Good health, Cor Malalties, Echocardiography, Ambulatory, Hypertension, purl.org/becyt/ford/3 [https], Hipertensió, ambulatory blood pressure monitoring, hypertension, hypertension management, treated hypertensive patients, TREATED HYPERTENSIVE PATIENTS, medicine.medical_specialty, Ambulatory blood pressure, CIENCIAS MÉDICAS Y DE LA SALUD, Heart Ventricles, treated hypertensive patient, Pressió sanguínia, 03 medical and health sciences, medicine, Albuminuria, Humans, Antihypertensive Agents, Protocol (science), business.industry, Consolidated Standards of Reporting Trials, Presión sanguínea, Good clinical practice, Emergency medicine, business, Declaration of Helsinki, Assaigs clínics
Abstract: Introduction Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. Methods and analysis MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hypertensive patients from about 40 secondary care clinical centres worldwide will be included -upon confirming presence of MUCH (repeated on treatment OBP
Published: 2018

22. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets

Author: Krzysztof Narkiewicz, Josep Redon, Giuseppe Mancia, Aud Stenehjem, Michel Burnier, Ingrid Os, Enrico Agabiti Rosei, Sverre E. Kjeldsen, Philippe van de Borne, Kjeldsen, S, Stenehjem, A, Os, I, Van de Borne, P, Burnier, M, Narkiewicz, K, Redon, J, Agabiti Rosei, E, and Mancia, G
Subjects: medicine.medical_specialty, Blood Pressure, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Internal Medicine, medicine, Humans, Frail elderly, 030212 general & internal medicine, Intensive care medicine, Blood pressure-lowering treatment, Aged, Aged, 80 and over, octogenarian, business.industry, General Medicine, blood pressure target, medicine.disease, Comorbidity, elderly patient, Europe, Blood pressure, European Society of Hypertension, Hypertension, Isolated systolic hypertension, Treatment decision making, Cardiology and Cardiovascular Medicine, business
Abstract: The European Society of Hypertension recommend the following main rules for treatment of hypertension in elderly and octogenarians: 1) In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 140 mmHg and 150 mmHg. 2) In fit elderly patients less than 80 years old treatment may be considered at SBP ≥ 140 mmHg with a target SBP
Published: 2016

23. Expertise: No Longer a Sine Qua Non for Guideline Authors?

Author: Sverre E. Kjeldsen, Roland E. Schmieder, Franz H. Messerli, Tomasz Grodzicki, John B. Kostis, B. Williams, Stephane Laurent, Peter S. Sever, Ernesto L. Schiffrin, Josep Redon, James R. Sowers, Neil Poulter, Stanley S. Franklin, Luis M. Ruilope, Vasilios Papademetriou, Allan B. Schwartz, Frans H. Leenen, Michel Burnier, Michael A. Weber, Enrico Agabiti-Rosei, Krzysztof Narkiewicz, William J. Elliott, Kazuomi Kario, Jan A. Staessen, Gianfranco Parati, Giuseppe Mancia, Louis Hofstetter, Ji-Guang Wang, Stefano F. Rimoldi, Per Lund-Johansen, Messerli, F, Hofstetter, L, Agabiti Rosei, E, Burnier, M, Elliott, W, Franklin, S, Grodzicki, T, Kario, K, Kjeldsen, S, Kostis, J, Laurent, S, Leenen, F, Lund Johansen, P, Mancia, G, Narkiewicz, K, Papademetriou, V, Parati, G, Poulter, N, Redon, J, Rimoldi, S, Ruilope, L, Schiffrin, E, Schmieder, R, Schwartz, A, Sever, P, Sowers, J, Staessen, J, Wang, J, Weber, M, and Williams, B
Subjects: medicine.medical_specialty, Medical education, Guard (information security), Sine qua non, business.industry, media_common.quotation_subject, Alternative medicine, MEDLINE, 1103 Clinical Sciences, Guideline, 030204 cardiovascular system & hematology, 1102 Cardiovascular Medicine And Haematology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Annals, Cardiovascular System & Hematology, Internal Medicine, medicine, Quality (business), Professional association, 030212 general & internal medicine, business, Psychiatry, media_common
Abstract: See Related Editorial, pp 238–239 > Quis custodiet ipsos custodes?—Who will guard the guards themselves? > > —Decimus Iunius Iuvenalis (Juvenal), 1st–2nd century AD, Satire VI, lines 347–348 Guidelines are traditionally scripted by a panel of experts who are intimately familiar with the topic in question. Practicing physicians inherently trust guideline authors and rarely ever question their expertise, especially when guidelines are endorsed by such venerable societies as the American College of Physicians (ACP) and the American Academy of Family Practitioners (AAFP) and are published in high-impact journals, such as the Annals of Internal Medicine . The >250 000 members of the ACP and AAFP have come to expect that any set of clinically meaningful guidelines has been put together by authors who were selected because of their outstanding skills and expertise pertaining to the topic in question. Thus, there is little if any reason to voice doubt as to the validity of published guidelines The Free Dictionary defines expertise as special skills or knowledge acquired by a person through education, training, or experience. For a physician unfamiliar with the experts, there are several simple ways to get a grasp on the quality and quantity of expertise: 1. One can scrutinize the publication list of the experts to assess how often they have been involved with the guideline topic. Any expert is expected to be well published in the specific area of the expertise. 2. One may take into account an expert’s membership in professional organizations pertaining to the subject matter. Obviously, membership and participation in annual meetings demonstrates an ongoing interest in the guideline topic. 3. One may examine whether the physician/scientist has been invited to serve on editorial boards of journals dealing with the topic in question. Being a member of an editorial board and peer reviewing submissions attest to some expertise pertaining to the …
Published: 2017

24. Expertise

Author: Bryan Williams, Peter W. de Leeuw, Franz H. Messerli, Neil Poulter, Stefano F. Rimoldi, James R. Sowers, John B. Kostis, Roland E. Schmieder, Krzysztof Narkiewicz, Stéphane Laurent, Michael A. Weber, Louis Hofstetter, Kazuomi Kario, Enrico Agabiti-Rosei, Josep Redon, Gianfranco Parati, Luis M. Ruilope, Sverre E. Kjeldsen, William J. Elliott, Jan A. Staessen, Ji-Guang Wang, Giuseppe Mancia, Vasilios Papademetriou, Frans H. H. Leenen, Stanley S. Franklin, Ernesto L. Schiffrin, Per Lund-Johansen, Michel Burnier, Peter S. Sever, Tomasz Grodzicki, Allan B. Schwartz, RS: CARIM - R3.02 - Hypertension and target organ damage, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Alg Interne Geneeskunde (9), Messerli, F, Hofstetter, L, Agabiti Rosei, E, Burnier, M, Elliott, W, Franklin, S, Grodzicki, T, Kario, K, Kjeldsen, S, Kostis, J, Laurent, S, Leenen, F, Lund Johansen, P, Mancia, G, Narkiewicz, K, Papademetriou, V, Parati, G, Poulter, N, Redon, J, Rimoldi, S, Ruilope, L, Schiffrin, E, Schmieder, R, Schwartz, A, Sever, P, Sowers, J, Staessen, J, Wang, J, Weber, M, Williams, B, and De Leeuw, P
Subjects: Pediatrics, medicine.medical_specialty, hypertension, Physiology, Sine qua non, Alternative medicine, MEDLINE, 030204 cardiovascular system & hematology, 1102 Cardiovascular Medicine And Haematology, 03 medical and health sciences, Professional Competence, 0302 clinical medicine, Internal Medicine, medicine, Humans, BLOOD-PRESSURE TARGETS, guidelines, 030212 general & internal medicine, Set (psychology), Societies, Medical, METAANALYSIS, ANGIO-EDEMA, OLDER, Medical education, Science & Technology, business.industry, 1103 Clinical Sciences, AGED 60 YEARS, Guideline, Professional competence, 3. Good health, Peripheral Vascular Disease, Cardiovascular System & Hematology, Practice Guidelines as Topic, Cardiovascular System & Cardiology, expertise, INHIBITORS, Cardiology and Cardiovascular Medicine, business, Life Sciences & Biomedicine, guideline
Abstract: Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable. ispartof: Journal Of Hypertension vol:35 issue:8 pages:1564-1566 ispartof: location:Netherlands status: published
Published: 2017

25. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018)

Author: Williams, Bryan, Mancia, Giuseppe, Spiering, Wilko, Agabiti Rosei, Enrico, Azizi, Michel, Burnier, Michel, Clement, Denis L, Coca, Antonio, de Simone, Giovanni, Dominiczak, Anna, Kahan, Thomas, Mahfoud, Felix, Redon, Josep, Ruilope, Luis, Zanchetti, Alberto, Kerins, Mary, Kjeldsen, Sverre E, Kreutz, Reinhold, Laurent, Stephane, Lip, Gregory Y H, McManus, Richard, Narkiewicz, Krzysztof, Ruschitzka, Frank, Schmieder, Roland E, Shlyakhto, Evgeny, Tsioufis, Costas, Aboyans, Victor, Desormais, Ileana, De Backer, Guy, Heagerty, Anthony M, Agewall, Stefan, Bochud, Murielle, Borghi, Claudio, Boutouyrie, Pierre, Brguljan, Jana, Bueno, Héctor, Caiani, Enrico G, Carlberg, Bo, Chapman, Neil, Cífková, Renata, Cleland, John G F, Collet, Jean-Philippe, Coman, Ioan Mircea, de Leeuw, Peter W, Delgado, Victoria, Dendale, Paul, Diener, Hans-Christoph, Dorobantu, Maria, Fagard, Robert, Farsang, Csaba, Ferrini, Marc, Graham, Ian M, Grassi, Guido, Haller, Hermann, Hobbs, F D Richard, Jelakovic, Bojan, Jennings, Catriona, Katus, Hugo A, Kroon, Abraham A, Leclercq, Christophe, Lovic, Dragan, Lurbe, Empar, Manolis, Athanasios J, McDonagh, Theresa A, Messerli, Franz, Muiesan, Maria Lorenza, Nixdorff, Uwe, Olsen, Michael Hecht, Parati, Gianfranco, Perk, Joep, Piepoli, Massimo Francesco, Polonia, Jorge, Ponikowski, Piotr, Richter, Dimitrios J, Rimoldi, Stefano F, Roffi, Marco, Sattar, Naveed, Seferovic, Petar M, Simpson, Iain A, Sousa-Uva, Miguel, Stanton, Alice V, van de Borne, Philippe, Vardas, Panos, Volpe, Massimo, Wassmann, Sven, Windecker, Stephan, Zamorano, Jose Luis, Barbato, Emanuele, Dean, Veronica, Fitzsimons, Donna, Gaemperli, Oliver, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Knuuti, Juhani, Lancellotti, Patrizio, Rosei, Enrico Agabiti, Januszewics, Andrzej, Manolis, Athanasios, Benkhedda, Salim, Zelveian, Parounak, Siostrzonek, Peter, Najafov, Ruslan, Pavlova, Olga, De Pauw, Michel, Dizdarevic-Hudic, Larisa, Raev, Dimitar, Karpettas, Nikos, Linhart, Aleš, Shaker, Amin Fouad, Viigimaa, Margus, Metsärinne, Kaj, Vavlukis, Marija, Halimi, Jean-Michel, Pagava, Zurab, Schunkert, Heribert, Thomopoulos, Costas, Páll, Dénes, Andersen, Karl, Shechter, Michael, Mercuro, Giuseppe, Bajraktari, Gani, Romanova, Tatiana, Trušinskis, Kārlis, Saade, Georges A, Sakalyte, Gintare, Noppe, Stéphanie, DeMarco, Daniela Cassar, Caraus, Alexandru, Wittekoek, Janneke, Aksnes, Tonje Amb, Jankowski, Piotr, Vinereanu, Dragos, Baranova, Elena I, Foscoli, Marina, Dikic, Ana Djordjevic, Filipova, Slavomira, Fras, Zlatko, Bertomeu-Martínez, Vicente, Burkard, Thilo, Sdiri, Wissem, Aydogdu, Sinan, Sirenko, Yuriy, Brady, Adrian, Weber, Thomas, Lazareva, Irina, Backer, Tine De, Sokolovic, Sekib, Widimsky, Jiri, Pörsti, Ilkka, Denolle, Thierry, Krämer, Bernhard K, Stergiou, George S, Miglinas, Marius, Gerdts, Eva, Tykarski, Andrzej, de Carvalho Rodrigues, Manuel, Chazova, Irina, Segura, Julian, Gottsäter, Anders, Pechère-Bertschi, Antoinette, Erdine, Serap, Williams, Bryan, Mancia, Giuseppe, Spiering, Wilko, Rosei, Enrico Agabiti, Azizi, Michel, Burnier, Michel, Clement, Denis L., Coca, Antonio, De Simone, Giovanni, Dominiczak, Anna, Kahan, Thoma, Mahfoud, Felix, Redon, Josep, Ruilope, Lui, Zanchetti, Alberto, Kerins, Mary, Kjeldsen, Sverre E., Kreutz, Reinhold, Laurent, Stephane, Lip, Gregory Y. H., Mcmanus, Richard, Narkiewicz, Krzysztof, Ruschitzka, Frank, Schmieder, Roland E., Shlyakhto, Evgeny, Tsioufis, Costa, Aboyans, Victor, Desormais, Ileana, De Backer, Guy, Heagerty, Anthony M., Agewall, Stefan, Bochud, Murielle, Borghi, Claudio, Boutouyrie, Pierre, Brguljan, Jana, Bueno, Héctor, Caiani, Enrico G., Carlberg, Bo, Chapman, Neil, Cífková, Renata, Cleland, John G. F., Collet, Jean-Philippe, Coman, Ioan Mircea, De Leeuw, Peter W., Delgado, Victoria, Dendale, Paul, Diener, Hans-Christoph, Dorobantu, Maria, Fagard, Robert, Farsang, Csaba, Ferrini, Marc, Graham, Ian M., Grassi, Guido, Haller, Hermann, Hobbs, F. D. Richard, Jelakovic, Bojan, Jennings, Catriona, Katus, Hugo A., Kroon, Abraham A., Leclercq, Christophe, Lovic, Dragan, Lurbe, Empar, Manolis, Athanasios J., Mcdonagh, Theresa A., Messerli, Franz, Muiesan, Maria Lorenza, Nixdorff, Uwe, Olsen, Michael Hecht, Parati, Gianfranco, Perk, Joep, Piepoli, Massimo Francesco, Polonia, Jorge, Ponikowski, Piotr, Richter, Dimitrios J., Rimoldi, Stefano F., Roffi, Marco, Sattar, Naveed, Seferovic, Petar M., Simpson, Iain A., Sousa-Uva, Miguel, Stanton, Alice V., Van De Borne, Philippe, Vardas, Pano, Volpe, Massimo, Wassmann, Sven, Windecker, Stephan, Zamorano, Jose Luis, University College of London [London] (UCL), University College London Hospitals (UCLH), Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université de Lausanne = University of Lausanne (UNIL), Institut de Mathématiques de Marseille (I2M), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU), BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Danderyds sjukhus = Danderyd University Hospital, Universitätsklinikum des Saarlandes, Universitat de València (UV), Hospital 12 de Octubre, Oslo University Hospital [Oslo], Clinical Pharmacology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), University of Liverpool, Aalborg University [Denmark] (AAU), Nuffield Department of Primary Care Health Sciences, University of Oxford, University of Oxford, Medical University of Gdańsk, University Heart Centre Freiburg - Bad Krozingen, Med Klinik IV, Univ.-Klinik Erlangen-Nürnberg, Almazov National Medical Research Centre (St. Petersburg), National and Kapodistrian University of Athens (NKUA), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de cardiologie [CHU Limoges], CHU Limoges, Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], Agabiti Rosei, Enrico, Clement, Denis L, de Simone, Giovanni, Kjeldsen, Sverre E, Lip, Gregory Y H, McManus, Richard, Schmieder, Roland E, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet [Stockholm], Chercheur indépendant, Department of Cardiology, Birmingham City Hospital, Department of Public Health, University of Gent, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento di Elettronica, Informazione e Bioingegneria (DEIB), Politecnico di Milano [Milan] (POLIMI), 2nd Department of Internal Medicine, Hasselt University (UHasselt), Universität Duisburg-Essen [Essen], Australian Museum, Australian Museum [Sydney], Division of Nephrology and Hypertension, Department of Medicine, Hanover Medical School, Department of Earth Science, Durham University, School of Health and Caring Sciences, Linnaeus University, Department of Pathological Biochemistry, Royal Infirmary, Karolinska Institute, karolinska institute, 'Federico II' University of Naples Medical School, Hospital General Universitario 'Gregorio Marañón' [Madrid], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU de Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), St. Michael's Hospital, Heidelberg University Hospital [Heidelberg], Turku PET Centre, University of Turku, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA-Research), Université de Liège, Wroclaw Medical University, Servicio de Pediatría, Consorcio Hospital General Universitario de Valencia, Institute of Social and Preventive Medicine, Lausanne university hospital, Department of Internal Medicine, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Aging and Clinical Nephrology, Food Science and Technology, Université Francois Rabelais [Tours], Medizinische Klinik II, Universität zu Lübeck [Lübeck], Warsaw University of Technology [Warsaw], Cardiology, University and Emergency Hospital, IRCELYON-Catalytic and Atmospheric Reactivity for the Environment (CARE), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), University of Sheffield [Sheffield], Faculty of metals engineering and industrial computer science, Centre of Cardiology, North Estonia Medical Centre, Medical School, University of Tampere [Finland], Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], IRCCS Istituto Auxologico Italiano, University of Zurich, Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hasselt University, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Università di Bologna [Bologna] (UNIBO)-Aging and Clinical Nephrology, Universität zu Lübeck [Lübeck] - University of Lübeck [Lübeck], IRCELYON-Caractérisation et remédiation des polluants dans l'air et l'eau (CARE), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Service de cardiologie et maladies vasculaires [CHU de Rennes], Diener, Hans Christoph (Beitragende*r), Williams, B, Mancia, G, Spiering, W, Agabiti Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, de Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, and Grassi, G
Subjects: Male, Lifestyle intervention, [SDV]Life Sciences [q-bio], Medizin, Secondary hypertension, 030204 cardiovascular system & hematology, Guideline, Hypertension-mediated organ damage, Blood pressure treatment thresholds and targets, 0302 clinical medicine, Medicine, 030212 general & internal medicine, Disease management (health), 610 Medicine & health, Lifestyle interventions, Societies, Medical, ComputingMilieux_MISCELLANEOUS, Disease Management, Blood pressure, Blood pressure measurement, Combination therapy, Device therapy, Drug therapy, Guidelines, Hypertension, Cardiology and Cardiovascular Medicine, Europe, Arterial hypertension, blood pressure control, guidelines, 10209 Clinic for Cardiology, Female, medicine.medical_specialty, Blood pressure treatment thresholds and target, MEDLINE, Cardiology, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, Pharmacotherapy, Blood pressure treatmentthresholds and targets, Journal Article, Humans, Hypertension diagnosis, Intensive care medicine, Antihypertensive Agents, business.industry, medicine.disease, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract: International audience; : Document reviewers: Guy De Backer (ESC Review Co-ordinator) (Belgium), Anthony M. Heagerty (ESH Review Co-ordinator) (UK), Stefan Agewall (Norway), Murielle Bochud (Switzerland), Claudio Borghi (Italy), Pierre Boutouyrie (France), Jana Brguljan (Slovenia), Héctor Bueno (Spain), Enrico G. Caiani (Italy), Bo Carlberg (Sweden), Neil Chapman (UK), Renata Cifkova (Czech Republic), John G. F. Cleland (UK), Jean-Philippe Collet (France), Ioan Mircea Coman (Romania), Peter W. de Leeuw (The Netherlands), Victoria Delgado (The Netherlands), Paul Dendale (Belgium), Hans-Christoph Diener (Germany), Maria Dorobantu (Romania), Robert Fagard (Belgium), Csaba Farsang (Hungary), Marc Ferrini (France), Ian M. Graham (Ireland), Guido Grassi (Italy), Hermann Haller (Germany), F. D. Richard Hobbs (UK), Bojan Jelakovic (Croatia), Catriona Jennings (UK), Hugo A. Katus (Germany), Abraham A. Kroon (The Netherlands), Christophe Leclercq (France), Dragan Lovic (Serbia), Empar Lurbe (Spain), Athanasios J. Manolis (Greece), Theresa A. McDonagh (UK), Franz Messerli (Switzerland), Maria Lorenza Muiesan (Italy), Uwe Nixdorff (Germany), Michael Hecht Olsen (Denmark), Gianfranco Parati (Italy), Joep Perk (Sweden), Massimo Francesco Piepoli (Italy), Jorge Polonia (Portugal), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece), Stefano F. Rimoldi (Switzerland), Marco Roffi (Switzerland), Naveed Sattar (UK), Petar M. Seferovic (Serbia), Iain A. Simpson (UK), Miguel Sousa-Uva (Portugal), Alice V. Stanton (Ireland), Philippe van de Borne (Belgium), Panos Vardas (Greece), Massimo Volpe (Italy), Sven Wassmann (Germany), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain).The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines.
Published: 2018

26. Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study

Author: Desideri, Giovambattista, Virdis, Agostino, Casiglia, Edoardo, Borghi Claudio, Cicero AFG, Muiesan ML, Rosei EA, Salvetti M, Ungar A, Rivasi G, Pontremoli R, Viazzi F, Desideri G, Grassi G, Bombelli M, Facchetti R, Ferri C, Bernardino B, Galletti F, D'Elia L, Palatini P, Casiglia E, Tikhonoff V, Barbagallo CM, Verdecchia P, Virdis, Pietrina, Masi S, Mallamaci F, Cirillo M, Rattazzi M, Pauletto P, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Iaccarino G, Nazzaro, Desideri, Giovambattista, Virdis, Agostino, Casiglia, Edoardo, Borghi, Claudio, 644 Desideri, G, Virdis, A, Casiglia, E, Borghi, C, Cicero, A, Muiesan, M, Agabiti-Rosei, E, Salvetti, M, Ungar, A, Rivasi, G, Pontremoli, R, Viazzi, Grassi, G, Bombelli, M, Facchetti, R, Ferri, C, Bernardino, B, Galetti, F, D’Elia, L, Palatini, P, Tickhonoff, V, Barbagallo, C, Verdecchia, P, Masi, S, Mallamaci, F, Cirillo, M, Gesualdo, L, Mazza, A, Giannattasio, C, Maloberti, A, Ratazzi, M, Pauletto, P, Volpe, M, Tocci, G, Iaccarino, G, Nazzaro, P, Cicero, Afg, Muiesan, Ml, Rosei, Ea, Viazzi, F, Desideri, G, Galletti, F, D'Elia, L, Tikhonoff, V, Barbagallo, Cm, Virdis, Pietrina, Rattazzi, M, Cirillo, P, and Nazzaro
Subjects: medicine.medical_specialty, Settore MED/09 - Medicina Interna, Prognosi, Epidemiology, Population, Disease, Hyperuricemia, 030204 cardiovascular system & hematology, Risk Assessment, Cardiovascular disease, Uric acid, Biomarkers, Cardiovascular Diseases, Humans, Italy, Prognosis, Research Design, Retrospective Studies, Risk Factors, Uric Acid, Internal Medicine, Cardiology and Cardiovascular Medicine, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Retrospective Studie, Internal medicine, medicine, Risk factor, education, 030203 arthritis & rheumatology, education.field_of_study, business.industry, Risk Factor, Retrospective cohort study, Biomarker, medicine.disease, chemistry, business, Risk assessment, Human
Abstract: The relevance of cardiovascular role played by levels of serum uric acid is dramatically growing, especially as cardiovascular risk factor potentially able to exert either a direct deleterious impact or a synergic effect with other cardiovascular risk factors. At the present time, it still remains undefined the threshold level of serum uric acid able to contribute to the cardiovascular risk. Indeed, the available epidemiological case studies are not homogeneous, and some preliminary data suggest that the so-called "cardiovascular threshold limit" may substantially differ from that identified as a cut-off able to trigger the acute gout attack. In such scenario, there is the necessity to clarify and quantify this threshold value, to insert it in the stratification of risk algorithm scores and, in turn, to adopt proper prevention and correction strategies. The clarification of the relationship between circulating levels of uric acid and cardio-nephro-metabolic disorders in a broad sample representative of general population is critical to identify the threshold value of serum uric acid better discriminating the increased risk associated with uric acid. The Uric acid Right for heArt Health (URRAH) project has been designed to define, as primary objective, the level of uricemia above which the independent risk of cardiovascular disease may increase in a significantly manner in a general Italian population.
Published: 2018

27. Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?

Author: Pantelis Sarafidis, Ioannis Andrikou, Costas Tsioufis, Andreas Koureas, Belen Ponte, Dimitrios Tousoulis, Enrico Agabiti-Rosei, Menno Pruijm, Michel Burnier, Giuseppe Mancia, Tsioufis, C, Andrikou, I, Pruijm, M, Ponte, B, Sarafidis, P, Koureas, A, Tousoulis, D, Agabiti-Rosei, E, Mancia, G, and Burnier, M
Subjects: Pathology, medicine.medical_specialty, Urinary albumin, Physiology, 030232 urology & nephrology, Renal function, Secondary hypertension, Newly diagnosed, 030204 cardiovascular system & hematology, urologic and male genital diseases, Kidney, 03 medical and health sciences, 0302 clinical medicine, Renal injury, Color doppler ultrasonography, secondary hypertension, Internal Medicine, Medicine, Humans, Ultrasonography, Doppler, Color, Ultrasonography, ddc:616, business.industry, Renal ultrasound, risk assessment, Ultrasonography, Doppler, medicine.disease, renal resistance, medicine.anatomical_structure, Hypertension, Radiology, business, Cardiology and Cardiovascular Medicine, chronic kidney disease, Glomerular Filtration Rate
Abstract: European Society of Hypertension/European Society of Cardiology guidelines recommend calculation of estimated glomerular filtration rate and evaluation of urinary albumin excretion rate as routine tests in the initial evaluation and during the follow-up of all hypertensive patients. However, from a clinical point of view, renal ultrasound - a noninvasive, readily available and cheap imaging modality - could contribute to the better evaluation of a hypertensive patient by identifying common causes of secondary hypertension (HTN) originating from the kidney and more recently by detecting renal injury in severe or long-standing essential HTN by measuring renal resistive indexes. The purpose of this review is to summarize the actual evidence which could support a larger use of renal ultrasound in the work-up of patients with newly diagnosed HTN.
Published: 2018

28. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized 'Z' Studies

Author: Stefano Omboni, Gianfranco Parati, Enrico Agabiti-Rosei, Ettore Malacco, Athanasios J. Manolis, Claudio Napoli, Pietro Amedeo Modesti, Claudio Borghi, Omboni, Stefano, Malacco, Ettore, Napoli, Claudio, Modesti, Pietro Amedeo, Manolis, Athanasio, Parati, Gianfranco, Agabiti Rosei, Enrico, Borghi, Claudio, Agabiti-Rosei, Enrico, Omboni, S, Malacco, E, Napoli, C, Modesti, P, Manolis, A, Parati, G, Agabiti rosei, E, and Borghi, C
Subjects: Blood Glucose, Male, Captopril, Office blood pressure, Blood Pressure, Pulse Wave Analysi, 030204 cardiovascular system & hematology, Pharmacology, Essential hypertension, chemistry.chemical_compound, 0302 clinical medicine, Hydrochlorothiazide, Ambulatory blood pressure, Angiotensin converting enzyme inhibitors, Angiotensin II receptor blockers, Irbesartan, Thiazide diuretics, Zofenopril, Medicine (all), Pharmacology (medical), Medicine, 030212 general & internal medicine, Inflammation Mediator, Tetrazole, Randomized Controlled Trials as Topic, Medicine(all), biology, Angiotensin Receptor Antagonist, Diabetes Mellitu, General Medicine, Lipid, Middle Aged, Antihypertensive Agent, C-Reactive Protein, Hypertension, Aged, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Biomarkers, Biphenyl Compounds, Diabetes Mellitus, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation Mediators, Lipids, Pulse Wave Analysis, Risk Factors, Tetrazoles, Vascular Stiffness, Human, medicine.drug, medicine.medical_specialty, Urology, 03 medical and health sciences, business.industry, Thiazide diuretic, Risk Factor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin-converting enzyme, Biomarker, medicine.disease, Blood pressure, chemistry, ACE inhibitor, Biphenyl Compound, biology.protein, Angiotensin II receptor blocker, Angiotensin converting enzyme inhibitor, business, Vascular Stiffne
Abstract: none 8 si Combinations between an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ) are among the recommended treatments for hypertensive patients uncontrolled by monotherapy. Four randomized, double-blind, parallel group studies with a similar design, including 1469 hypertensive patients uncontrolled by a previous monotherapy and with ≥1 cardiovascular risk factor, compared the efficacy of a combination of a sulfhydryl ACE inhibitor (zofenopril at 30 or 60 mg) or an ARB (irbesartan at 150 or 300 mg) plus HCTZ 12.5 mg. The extent of blood pressure (BP)-lowering was assessed in the office and over 24 h. Pleiotropic features of the treatments were evaluated by studying their effect on systemic inflammation, organ damage, arterial stiffness, and metabolic biochemical parameters. Both treatments similarly reduced office and ambulatory BPs after 18–24 weeks. In the ZODIAC study a larger reduction in high sensitivity C reactive protein (hs-CRP) was observed under zofenopril (−0.52 vs. +0.97 mg/dL under irbesartan, p = 0.001), suggesting a potential protective effect against the development of atherosclerosis. In the ZENITH study the rate of carotid plaque regression was significantly larger under zofenopril (32% vs. 16%; p = 0.047). In the diabetic patients of the ZAMES study, no adverse effects of treatments on blood glucose and lipids as well as an improvement of renal function were observed. In patients with isolated systolic hypertension of the ZEUS study, a slight and similar improvement in renal function and small reductions in pulse wave velocity (PWV), augmentation index (AI), and central systolic BP were documented with both treatments. Thus, the fixed combination of zofenopril and HCTZ may have a relevant place in the treatment of high-risk or monotherapy-treated uncontrolled hypertensive patients requiring a more prompt, intensive, and sustained BP reduction, in line with the recommendations of current guidelines. none Omboni, Stefano; Malacco, Ettore; Napoli, Claudio; Modesti, Pietro Amedeo; Manolis, Athanasios; Parati, Gianfranco; Agabiti-Rosei, Enrico; Borghi, Claudio Omboni, Stefano; Malacco, Ettore; Napoli, Claudio; Modesti, Pietro Amedeo; Manolis, Athanasios; Parati, Gianfranco; Agabiti-Rosei, Enrico; Borghi, Claudio
Published: 2017

29. Beyond gout: uric acid and cardiovascular diseases

Author: Guido Grassi, E. Agabiti-Rosei, Agabiti Rosei, E, and Grassi, G
Subjects: Cardiac function curve, Xanthine Oxidase, medicine.medical_specialty, Gout, medicine.drug_class, Hemodynamics, Hyperuricemia, medicine.disease_cause, Bioinformatics, chemistry.chemical_compound, Cardiovascular Disease, Internal medicine, medicine, Humans, Xanthine oxidase, Xanthine oxidase inhibitor, business.industry, General Medicine, medicine.disease, Endocrinology, chemistry, Cardiovascular Diseases, Uric acid, business, Oxidative stress, Human
Abstract: This article discusses the results of clinical and experimental studies that examine the association of hyperuricemia and gout with cardiovascular (CV) disease.Key papers for inclusion were identified by a PubMed search, and articles were selected for their relevance to the topic, according to the authors' judgment.Significant progress has been made in confirming an association, possibly causal, between hyperuricemia and CV outcomes. Xantine-oxidase (XO) inhibitors appear to be the most promising agents for prevention and treatment of CV consequences associated with hyperuricemia. Several small and medium sized studies have examined the effect of these agents on CV function in a variety of patient populations. Improvements in measures of endothelial function, oxidative stress, cardiac function, hemodynamics, and certain inflammatory indices have been demonstrated. Compounds for XO inhibition with more specific clinical effects and fewer side effects than allopurinol may be promising options to further explore the therapeutic potential in patients with CV disease. It is too early to make clinical recommendations with regard to the benefits of using XO inhibitor allopurinol or the novel febuxostat in patients with asymptomatic increased UA levels and high CV risk because only a small number of studies have shown that they may be beneficial in terms of CV outcomes. More studies are therefore needed to determine the potential of these drugs for reducing the risk of developing CV disease.
Published: 2013

30. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents

Author: Asle Hirth, Elke Wühl, Enrico Agabiti-Rosei, Serap Erdine, Manish D. Sinha, Josep Redon, Empar Lurbe, Alberto Zanchetti, Mieczysław Litwin, Stella Stabouli, Tomáš Seeman, Giuseppe Mancia, Anna F. Dominiczak, Nicholas J. A. Webb, Cecilia Invitti, Franz Schaefer, Dénes Páll, J. Kennedy Cruickshank, Wolfgang Rascher, Lurbe, E, Agabiti-Rosei, E, Cruickshank, J, Dominiczak, A, Erdine, S, Hirth, A, Invitti, C, Litwin, M, Mancia, G, Pall, D, Rascher, W, Redon, J, Schaefer, F, Seeman, T, Sinha, M, Stabouli, S, Webb, N, Wühl, E, and Zanchetti, A
Subjects: Gerontology, medicine.medical_specialty, Adolescent, Physiology, Cardiovascular risk factors, Public policy, Blood Pressure, Disease, Comorbidity, 030204 cardiovascular system & hematology, Klinikai orvostudományok, European, Management of high blood pressure, 03 medical and health sciences, 0302 clinical medicine, Central blood pressure, Risk Factors, 030225 pediatrics, medicine, Internal Medicine, Prevalence, Humans, Clinical significance, cardiovascular diseases, Intensive care medicine, Child, Children, Society of hypertension, Antihypertensive Agents, Out of office blood pressure, business.industry, Public health, Risk Factor, Blood Pressure Determination, Orvostudományok, Recommendation, medicine.disease, 3. Good health, Antihypertensive Agent, Blood pressure, Hypertension, business, Cardiology and Cardiovascular Medicine, Human
Abstract: Increasing prevalence of hypertension (HTN) in children and adolescents has become a significant public health issue driving a considerable amount of research. Aspects discussed in this document include advances in the definition of HTN in 16 year or older, clinical significance of isolated systolic HTN in youth, the importance of out of office and central blood pressure measurement, new risk factors for HTN, methods to assess vascular phenotypes, clustering of cardiovascular risk factors and treatment strategies among others. The recommendations of the present document synthesize a considerable amount of scientific data and clinical experience and represent the best clinical wisdom upon which physicians, nurses and families should base their decisions. In addition, as they call attention to the burden of HTN in children and adolescents, and its contribution to the current epidemic of cardiovascular disease, these guidelines should encourage public policy makers to develop a global effort to improve identification and treatment of high blood pressure among children and adolescents.
Published: 2016

31. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke

Author: Csaba Farsang, Antonio Coca, Xin-Hua Zhang, Giuseppe Mancia, Arman Postadzhiyan, Krzysztof Narkiewicz, Stéphane Laurent, Nieves Martell-Claros, Fernando Pinto, Yuriy Sirenko, John T. O'Brien, Renata Cifkova, Bojan Jelaković, Guido Grassi, Irina Lazareva, Maria Dorobantu, Zhaosu Wu, Rok Accetto, Vincenzo Silani, Chengbin Xu, Giovanni Corrao, Eivind Berge, Philippos Stylianou, Dror Dicker, Gianfranco Parati, Yuqing Zhang, Dragan Lovic, Lorenza Scotti, Gary A. Ford, Roland E. Schmieder, Michel Burnier, Lisheng Liu, Marco Stramba-Badiale, Margus Viigimaa, Anna F. Dominiczak, Ting Rui Guan, Jose L. Rodicio, Alexandra Konradi, Hengge Xie, Athanasios J. Manolis, Enrico Agabiti-Rosei, Josep Redon, Peter M. Nilsson, Gangzhi Wei, Xuezhong Zhang, Dingliang Zhu, Alberto Zanchetti, Maciej Banach, Grzegorz Bilo, Antonella Zambon, Luis M. Ruilope, Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, STRAMBA-BADIALE, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Guan, T, Zhang, Y, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, and Ford, G
Subjects: medicine.medical_specialty, Physiology, business.industry, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Blood pressure, Sprint, Shot (pellet), Internal Medicine, Physical therapy, Medicine, 030212 general & internal medicine, Cardiology and Cardiovascular Medicine, business, Stroke
Published: 2016

32. Chronic disease in the ethnic minority and migrant groups: time for a paradigm shift in Europe

Author: Pietro Amedeo Modesti, Enrico Agabiti Rosei, Gianfranco Parati, Domenico Prisco, Francesco Perticone, Modesti, P, Perticone, F, Parati, G, Agabiti Rosei, E, and Prisco, D
Subjects: Male, Transients and Migrants, medicine.medical_specialty, business.industry, Ethnic group, 030204 cardiovascular system & hematology, Europe, 03 medical and health sciences, 0302 clinical medicine, Chronic disease, Family medicine, Paradigm shift, Chronic Disease, medicine, Ethnicity, Emergency Medicine, Internal Medicine, Humans, Female, 030212 general & internal medicine, business, Delivery of Health Care, Minority Groups, Needs Assessment
Published: 2016

33. Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy

Author: Giuseppe Mancia, Enrico Agabiti Rosei, Roberto Pontremoli, Massimo Volpe, Agostino Virdis, Claudio Borghi, Maria Lorenza Muiesan, Giuliano Tocci, Claudio Ferri, Gianfranco Parati, Tocci, G, Muiesan, M, Parati, G, Agabiti Rosei, E, Ferri, C, Virdis, A, Pontremoli, R, Mancia, G, Borghi, C, Volpe, M, Tocci, Giuliano, Muiesan, Maria L, Parati, Gianfranco, Agabiti Rosei, Enrico, Ferri, Claudio, Virdis, Agostino, Pontremoli, Roberto, Mancia, Giuseppe, Borghi, Claudio, and Volpe, Massimo
Subjects: 0301 basic medicine, Adult, Male, Pediatrics, medicine.medical_specialty, Cardiology and Cardiovascular Medicine, Internal Medicine, Endocrinology, Diabetes and Metabolism, Diastole, Health knowledge, Blood Pressure, 030204 cardiovascular system & hematology, Prehypertension, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Hypertension prevalence, Prevalence, Medicine, In real life, Humans, Prevalence, Awareness, Treatment, Control, Blood Pressure, Antihypertensive Agents, Antihypertensive medication, Aged, Practice, business.industry, Health Knowledge, Blood Pressure Determination, Female, Hypertension, Italy, Middle Aged, Health Knowledge, Attitudes, Practice, Diabetes and Metabolism, 030104 developmental biology, Blood pressure, Attitudes, business, Body mass index
Abstract: Estimates of blood pressure (BP) control in real life are not systematically collected in Italy. We evaluated trends in systolic/diastolic BP levels, as well as prevalence, awareness, treatment, and control rates of hypertension among adult individuals visiting open checkpoints during the 2004 to 2014 annual editions of World Hypertension Day. Hypertension was defined as BP level ≥140/90 mm Hg or use of antihypertensive medication, whereas BP control was defined as BP level
Published: 2016

34. Central Blood Pressure Measurements and Antihypertensive Therapy

Author: Michael F. O'Rourke, Giuseppe Mancia, Michel E. Safar, Enrico Agabiti-Rosei, Charalambos Vlachopoulos, Bryan Williams, Harold Smulyan, Mary J. Roman, Ian B. Wilkinson, Ji-Guang Wang, Agabiti Rosei, E, Mancia, G, O'Rourke, M, Roman, M, Safar, M, Smulyan, H, Wang, J, Wilkinson, I, Williams, B, and Vlachopoulos, C
Subjects: medicine.medical_specialty, organ damage, Diastole, Blood Pressure, heart and brain, Afterload, Predictive Value of Tests, Hypertension and CV risk, Internal Medicine, medicine, Humans, Systole, Intensive care medicine, Pulse wave velocity, Antihypertensive Agents, Aorta, Subclinical infection, business.industry, Blood Pressure Determination, Carotid Arteries, medicine.anatomical_structure, Blood pressure, Cardiovascular Diseases, Ventricle, Guidelines 2003, Hypertension, Practice Guidelines as Topic, Aortic pressure, business
Abstract: The 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension1 included 2 important novel recommendations: assessment of the total cardiovascular risk should be taken into account in the management of the hypertensive patient, and quantification of risk should include subclinical target organ damage. These guidelines acknowledged that central (aortic) blood pressure (BP), which is the pressure exerted on the heart and brain, may be different from the pressure that is measured at the arm. They also recognized that central pressure may be predictive of outcome in specific populations2 and differently affected by antihypertensive drugs. However, although these guidelines accepted that central augmentation index and pulse wave velocity may be important as measures of subclinical organ damage, they also stressed the need for prospective trials to establish their predictive values given that such studies were lacking at that time (2003). After publication of these guidelines, additional data have strengthened the pathophysiological importance of central BP. Clinical studies have indicated that central BP may have predictive value independent of the corresponding peripheral (brachial) BP. More importantly, recent large-scale trials have shown that central hemodynamics may provide a worthwhile treatment target. In addition, central hemodynamics can now be reliably assessed noninvasively with a number of devices. Accordingly, because arterial stiffening and central hemodynamics are markers and manifestations of organ damage, the pertinent key question is whether the balance of evidence on their importance and issues related to clinical practice allows for implementation in patient management. Central (aortic and carotid) pressures are pathophysiologically more relevant than peripheral pressures for the pathogenesis of cardiovascular disease.3,4 It is aortic systolic pressure that the left ventricle encounters during systole (afterload), and the aortic pressure during diastole is a determinant of coronary perfusion. Furthermore, the distending pressure in the …
Published: 2007

35. An update on hypertensive emergencies and urgencies

Author: Muiesan, Ml1, Salvetti, M, Amadoro, V, DI SOMMA, Salvatore, Perlini, S, Semplicini, A, Borghi, C, Volpe, M, Saba, Ps, Cameli, M, Ciccone, Mm, Maiello, M, Modesti, Pa, Novo, S, Palmiero, P, Scicchitano, P, Rosei, Ea, Pedrinelli, R, the Working Group on Hypertension, Prevention, Rehabilitation of the Italian Society of Cardiology, the Societa’ Italiana dell’Ipertensione Arteriosa, Muiesan, ML, Salvetti, M, Amadoro, V, Di Somma, S, Perlini, S, Semplicini, A, Borghi, C, Volpe, M, Saba, PS, Cameli, M, Ciccone, MM, Maiello, M, Modesti, PA, Novo, S, Palmiero, P, Scicchitano, P, Agabiti Rosei, E, Pedrinelli, R, Muiesan, Maria Lorenza, Salvetti, Massimo, Amadoro, Valentina, Di Somma, Salvatore, Perlini, Stefano, Semplicini, Andrea, Borghi, Claudio, Volpe, Massimo, Saba, Pier Sergio, Cameli, Matteo, Ciccone, Marco Matteo, Maiello, Maria, Modesti, Pietro Amedeo, Novo, Salvatore, Palmiero, Pasquale, Scicchitano, Pietro, Rosei, Enrico Agabiti, and Pedrinelli, Roberto
Subjects: medicine.medical_specialty, Acute coronary syndrome, hypertension, Demographics, hypertensive emergencie, acute coronary syndrome, hypertensive urgencie, Aneurysm, Dissecting, acute coronary syndrome, acute pulmonary oedema, hypertension, hypertensive urgencies, hypertensive emergencies, stroke, Terminology as Topic, Humans, Medicine, Hypertension diagnosis, Disease management (health), Intensive care medicine, Stroke, Acute pulmonary oedema, Emergencie, Heart Failure, business.industry, hypertensive urgencies, Disease Management, hypertensive emergencies, General Medicine, Aneurysm dissecting, acute pulmonary oedema, stroke, Cardiology and Cardiovascular Medicine, Hypertensive crisis, medicine.disease, Aortic Aneurysm, Aortic Dissection, Acute Disease, Emergencies, business, Human
Abstract: Severe acute arterial hypertension is usually defined as 'hypertensive crisis', although 'hypertensive emergencies' or 'hypertensive urgencies', as suggested by the Joint National Committee and the European Society of Hypertension, have completely different diagnostic and therapeutic approaches. The prevalence and demographics of hypertensive emergencies and urgencies have changed over the last four decades, but hypertensive emergencies and urgencies are still associated with significant morbidity and mortality. Different scientific societies have repeatedly produced up-to-date guidelines; however, the treatment of hypertensive emergencies and urgencies is still inappropriate, with potential clinical implications. This review focuses on hypertensive emergencies and urgencies management and treatment, as suggested by recent data.
Published: 2015

36. Inappropriate left ventricular mass: reliability and limitations of echocardiographic measurement for risk stratification and follow-up in single patients

Author: Giovanni de Simone, M. Lorenza Muiesan, Paolo Verdecchia, Giuseppe Mancia, Carlo Longhini, Antonello Ganau, Enrico Agabiti-Rosei, Muiesan, Ml, DE SIMONE, Giovanni, Ganau, A, Longhini, C, Verdecchia, P, Mancia, G, and AGABITI ROSEI E., ON BEHALF OF THE WORKING GROUP ON HEART AND HYPERTENSION OF ITALIAN SOCIETY OF HYPERTENSION
Subjects: Adult, Male, cardiovascular risk, arterial hypertension, medicine.medical_specialty, Physiology, Risk Assessment, Left ventricular mass, Stroke work, Predictive Value of Tests, work load, Ventricule gauche, Internal medicine, Internal Medicine, Humans, Medicine, Risk factor, Reliability (statistics), Aged, Observer Variation, Reproducibility, variability, business.industry, hypertrophy, left ventricular, Reproducibility of Results, Middle Aged, Prognosis, Surgery, Radiography, Echocardiography, Risk stratification, Cardiology, Female, Hypertrophy, Left Ventricular, Cardiology and Cardiovascular Medicine, business
Abstract: The appropriateness of left ventricular (LV) mass to cardiac workload may be calculated by the ratio of observed LV mass to the value predicted for an individual's sex, height, and stroke work at rest.To investigate test-retest reproducibility of observed/predicted LV mass in a single patient.We measured intraclass correlation and interval of agreement between two M-mode tracings, recorded both at the same session and 3-10 days apart in 200 participants (45 +/- 13 years, body mass index 25 +/- 4 kg/m; 99 hypertensive and 101 normotensive; 50% of each group were women) in 16 centres in Italy. Tracings were read by two observers in each centre.The values of observed/predicted LV mass value ranged from 40.78 to 215.50%. On the same day, the within-observer 90% interval of agreement between tracings 1 and 2 was -23 to +20%. For day-to-day test-retest within-observer variability (average three cycles), the 90% interval of agreement of the observed/predicted LV mass was -30 to +32%. The 90% interval of agreement of test-retest between-observer variability was -25 to +25%. The categorical consistency of retest in the identification of subjects with appropriate LV mass, classified in the first study (i.e.73% and128%), was 90% (k = 0.87).Measurement of the appropriateness of LV mass in single patients allows acceptable risk stratification, with a coefficient of consistency similar to that reported for LV mass. The probability of a true change (90% chance) in observed/predicted LV mass over time is maximized for a single-reader difference greater than 22%, although lesser differences might also have clinical relevance.
Published: 2006

37. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension

Author: Carlo Di Biagio, Bruno Magnani, Alberto Zanchetti, M. Lorenza Muiesan, Cesare Cuspidi, Catch investigators, Enrico Agabiti-Rosei, Massimo Salvetti, Laura Valagussa, Cuspidi, C, Muiesan, M, Valagussa, L, Salvetti, M, Di Biagio, C, Agabiti Rosei, E, Magnani, B, and Zanchetti, A
Subjects: Adult, Male, medicine.medical_specialty, Physiology, Diastole, Tetrazoles, Blood Pressure, Left ventricular hypertrophy, Essential hypertension, Hydrochlorothiazide, candesartan, enalapril, ventricular hypertrophy, Enalapril, Heart Rate, Ventricular hypertrophy, Internal medicine, Internal Medicine, medicine, Humans, cardiovascular diseases, Antihypertensive Agents, business.industry, Biphenyl Compounds, Middle Aged, medicine.disease, Candesartan, Treatment Outcome, Endocrinology, Blood pressure, Echocardiography, Hypertension, Cardiology, Benzimidazoles, Female, Hypertrophy, Left Ventricular, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: Background: A limited number of studies have evaluated the effect of angiotensin II receptor antagonists (AIIAs) on left ventricular hypertrophy (LVH) in comparison with other antihypertensive drugs, and no large study has compared AIIAs with angiotensin-converting enzyme inhibitors (ACEIs). Methods and results: The CATCH (Candesartan Assessment in the Treatment of Cardiac Hypertrophy) study was a multicenter prospective randomized double-blind trial comparing the effects of candesartan cilexetil (8-16 mg once daily) and enalapril (10-20 mg once daily) with possible addition of hydrochlorothiazide (12.5-25 mg once daily) on echocardiographic left ventricular mass index (LVMI), in 239 hypertensives with LVH (LVMI>120 g/m2 in men and >100 g/m2 in women). Two-dimensionally guided M-mode echocardiograms were carried out at screening (recruiting scan), randomization (baseline scan) and after 24 and 48 weeks of treatment. Baseline and treatment echocardiograms were read at two central labs without knowledge of the scan time sequence. In intention-to-treat (ITT) analyses (196 patients), systolic and diastolic blood pressures (SBP, DBP) were significantly and equally reduced by the two treatments. Candesartan and enalapril reduced LVMI to the same extent, i.e. by 15.0 and 13.1 g/m2 (-10.9 and -8.4%; P
Published: 2002

38. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence

Author: Ting Rui Guan, Maciej Banach, Renata Cifkova, Dror Dicker, Rok Accetto, Zhaosu Wu, Nieves Martell-Claros, Philippos Stylianou, Gangzhi Wei, Peter M. Nilsson, Lisheng Liu, Lorenza Scotti, Vincenzo Silani, Fernando Pinto, Antonella Zambon, Irina Lazareva, Maria Dorobantu, Chengbin Xu, Hayyan Wang, Xuezhong Zhang, Xin-Hua Zhang, Grzegorz Bilo, Arman Postadzhiyan, Anna F. Dominiczak, Luis M. Ruilope, Dingliang Zhu, Gianfranco Parati, John T. O'Brien, Yuriy Sirenko, Guido Grassi, Csaba Farsang, Antonio Coca, Serap Erdine, Margus Viigimaa, Krzysztof Narkiewicz, Stéphane Laurent, Giuseppe Mancia, Yuqing Zhang, Alberto Zanchetti, Michel Burnier, Bojan Jelaković, Gary A. Ford, Giovanni Corrao, Jose L. Rodicio, Alexandra Konradi, Hengge Xie, Athanasios J. Manolis, Eivind Berge, Enrico Agabiti-Rosei, Josep Redon, Dragan Lovic, Roland E. Schmieder, Marco Stramba-Badiale, Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Guan, T, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, and Ford, G
Subjects: Male, medicine.medical_specialty, Physiology, Hypercholesterolemia, Low density lipoprotein cholesterol, Blood Pressure, law.invention, Cognition, Randomized controlled trial, law, Recurrence, Internal medicine, blood pressure, cognitive decline, low-density, lipoprotein cholesterol, primary prevention, secondary prevention, stroke, Internal Medicine, Secondary Prevention, Medicine, Humans, Cognitive decline, Stroke, Beneficial effects, Randomized Controlled Trials as Topic, Secondary prevention, business.industry, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Cholesterol, LDL, medicine.disease, Primary Prevention, Blood pressure, Cholesterol, Cardiology, Physical therapy, lipids (amino acids, peptides, and proteins), Cardiology and Cardiovascular Medicine, business, Stroke incidence, Cognition Disorders, blood pressure, cognitive decline, low-density lipoprotein cholesterol, primary prevention, secondary prevention, stroke
Abstract: BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these treatments can prevent cognitive decline after stroke. RESULTS:: A review of existing data from randomized controlled trials confirms that solid evidence on optimal BP and LDL-C targets is missing, possible interactions between BP and LDL-C lowering treatments have never been directly investigated, and evidence in favour of a beneficial effect of BP or LDL-C lowering on cognitive decline is, at best, very weak. CONCLUSION:: A new, large randomized controlled trial is needed to determine the optimal level of BP and LDL-C for the prevention of recurrent stroke and cognitive decline.
Published: 2014

39. Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: Insights from the I-DEMAND study

Author: Annalisa Gonnella, E. Agabiti Rosei, Debora Garneri, Ettore Ambrosioni, M.L. Muiesan, Francesca Viazzi, Francesco V. Costa, Gastone Leonetti, Bruno Trimarco, Giovanna Leoncini, Achille C. Pessina, Roberto Pontremoli, Giacomo Deferrari, Massimo Volpe, Viazzi, F, Garneri, D, Leoncini, Laura, Gonnella, A, Muiesan, M. L, Ambrosioni, E, Costa, F. V, Leonetti, G, Pessina, Anna, Trimarco, Bruno, Volpe, M, Agabiti Rosei, E, Deferrari, G, and Pontremoli, R.
Subjects: Male, Cross-sectional study, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), Body Mass Index, Cohort Studies, Cardiovascular risk, Chronic kidney disease, Hypertension, Metabolic syndrome, Uric acid, Aged, Albuminuria, Biomarkers, Cardiovascular Diseases, Cross-Sectional Studies, Female, Glomerular Filtration Rate, Humans, Hyperuricemia, Italy, Logistic Models, Metabolic Syndrome X, Middle Aged, Multivariate Analysis, Prevalence, Renal Insufficiency, Chronic, Risk Factors, Uric Acid, Nutrition and Dietetics, Cardiology and Cardiovascular Medicine, Medicine (all), Endocrinology, Cardiovascular Disease, Renal Insufficiency, Chronic, Multivariate Analysi, education.field_of_study, Framingham Risk Score, Diabetes and Metabolism, Cohort study, Human, metabolic syndrome, hypertension, uric acid, cardiovascular risk, chronic kidney disease, medicine.medical_specialty, Logistic Model, Population, Internal medicine, medicine, education, Cross-Sectional Studie, business.industry, Risk Factor, Biomarker, medicine.disease, Microalbuminuria, Cohort Studie, business, Kidney disease
Abstract: The independent role of serum uric acid (SUA) as a marker of cardio-renal risk is debated. The aim of this study was to assess the relationship between SUA, metabolic syndrome (MS), and other cardiovascular (CV) risk factors in an Italian population of hypertensive patients with a high prevalence of diabetes.A total of 2429 patients (mean age 62 ± 11 years) among those enrolled in the I-DEMAND study were stratified on the basis of SUA gender specific quartiles. MS was defined according to the NCEP-ATP III criteria, chronic kidney disease (CKD) as an estimated GFR (CKD-Epi)60 ml/min/1.73 m(2) or as the presence of microalbuminuria (albumin-to-creatinine ratio ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women). The prevalence of MS, CKD, and positive history for CV events was 72%, 43%, and 20%, respectively. SUA levels correlated with the presence of MS, its components, signs of renal damage and worse CV risk profile. Multivariate logistic regression analysis revealed that SUA was associated with a positive history of CV events and high Framingham risk score even after adjusting for MS and its components (OR 1.10, 95% CI 1.03-1.18; P = 0.0060; OR 1.28, 95% CI 1.15-1.42; P0.0001). These associations were stronger in patients without diabetes and with normal renal function.Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care. Intervention trials are needed to investigate whether the reduction of SUA levels favorably impacts outcome in patients at high CV risk.
Published: 2014

40. Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly

Author: Franchi, C, Salerno, F, Conca, A, Djade, Cd, Tettamanti, M, Pasina, L, Corrao, S, Marengoni, A, Marcucci, M, Mannucci, Pm, Nobili, A, Reposi, Investigators, Sparacio, E, Alborghetti, S, Di Costanzo, R, Prisco, D, Silvestri, E, Cenci, C, Barnini, T, Delitala, G, Carta, S, Atzori, S, Guarnieri, G, Zanetti, M, Spalluti, A, Serra, Mg, Bleve, Ma, Vanoli, M, Grignani, G, Casella, G, Gasbarrone, L, Maniscalco, G, Gunelli, M, Tirotta, D, Brucato, A, Ghidoni, S, Di Corato, P, Bernardi, M, Li Bassi, S, Santi, L, Agnelli, G, Iorio, A, Marchesini, E, Mannarino, E, Lupattelli, G, Rondelli, P, Paciullo, F, Fabris, F, Carlon, M, Turatto, F, Baroni, Mc, Zardo, M, Manfredini, R, Molino, C, Pala, M, Fabbian, F, Nuti, R, Valenti, R, Ruvio, M, Cappelli, S, Paolisso, G, Rizzo, Mr, Laieta, Mt, Salvatore, T, Sasso, Fc, Utili, R, Durante Mangoni, E, Pinto, D, Olivieri, O, Stanzial, Am, Fellin, R, Volpato, S, Fotini, S, Barbagallo, M, Dominguez, L, Plances, L, D'Angelo, D, Rini, G, Mansueto, P, Pepe, I, Licata, G, Calvo, L, Valenti, M, Borghi, C, Strocchi, E, Rinaldi, Er, Zoli, M, Fabbri, E, Magalotti, D, Auteri, A, Pasqui, Al, Puccetti, L, Pasini, Fl, Capecchi, Pl, Bicchi, M, Sabbà, C, Vella, Fs, Marseglia, A, Luglio, Cv, Palasciano, G, Modeo, Me, Aquilino, A, Raffaele, P, Pugliese, S, Capobianco, C, Postiglione, A, Barbella, Mr, De Stefano, F, Fenoglio, L, Brignone, C, Bracco, C, Giraudo, A, Musca, G, Cuccurullo, O, Cricco, L, Fiorentini, A, Cappellini, Md, Fabio, G, Seghezzi, S, De Amicis MM, Fargion, S, Bonara, P, Bulgheroni, M, Lombardi, R, Magrini, F, Massari, F, Tonella, T, Peyvandi, F, Tedeschi, A, Rossio, R, Moreo, G, Ferrari, B, Roncari, L, Monzani, V, Savojardo, V, Folli, C, Magnini, M, Mari, D, Rossi, Pd, Damanti, S, Prolo, S, Lilleri, Ms, Micale, G, Podda, M, Selmi, C, Meda, F, Accordino, S, Monti, V, Corazza, Gr, Miceli, E, Lenti, Mv, Padula, D, Balduini, Cl, Bertolino, G, Provini, S, Quaglia, F, Murialdo, G, Bovio, M, Dallegri, F, Ottonello, L, Quercioli, A, Barreca, A, Secchi, Mb, Ghelfi, D, Chin, Ws, Carassale, L, Caporotundo, S, Anastasio, L, Sofia, L, Carbone, M, Traisci, G, De Feudis, L, Di Carlo, S, Davì, G, Guagnano, Mt, Sestili, S, Bergami, E, Rizzioli, E, Cagnoni, C, Bertone, L, Manucra, A, Buratti, A, Tognin, T, Liberato, Nl, Bernasconi, G, Nardo, B, Bianchi, Gb, Giaquinto, S, Benetti, G, Quagliolo, M, Centenaro, Gr, Purrello, Francesco, Di Pino, A, Piro, Salvatore, Mancuso, G, Calipari, D, Bartone, M, Gullo, F, Cortellaro, M, Magenta, M, Perego, F, Meroni, Mr, Cicardi, M, Marina Magenta AG, Sacco, A, Bonelli, A, Dentamaro, G, Rozzini, R, Falanga, L, Giordano, A, Perin, Pc, Lorenzati, B, Gruden, G, Bruno, G, Montrucchio, G, Greco, E, Tizzani, P, Fera, G, Di Luca ML, Renna, D, Perciccante, A, Coralli, A, Tassara, R, Melis, D, Rebella, L, Menardo, G, Bottone, S, Sferrazzo, E, Ferri, C, Striuli, R, Scipioni, R, Salmi, R, Gaudenzi, P, Gamberini, S, Ricci, F, Morabito, C, Fava, R, Semplicini, A, Gottardo, L, Vendemiale, G, Serviddio, G, Forlano, R, Bolondi, L, Rasciti, L, Serio, I, Masala, C, Mammarella, A, Raparelli, V, Rossi Fanelli, F, Delfino, M, Amoroso, A, Violi, F, Basili, S, Perri, L, Serra, P, Fontana, V, Falcone, M, Landolfi, R, Grieco, A, Gallo, A, Zuccalà, G, Franceschi, F, De Marco, G, Chiara, C, Marta, S, Bellusci, M, Setti, D, Pedrazzoli, F, Romanelli, G, Pirali, C, Amolini, C, Rosei, Ea, Rizzoni, D, Castoldi, L, Picardi, A, Gentilucci, Uv, Mazzarelli, C, Gallo, P, Guasti, L, Castiglioni, L, Maresca, A, Squizzato, A, Contini, S, Molaro, M, Annoni, G, Corsi, M, Zazzetta, S, Bertolotti, M, Mussi, C, Scotto, R, Ferri, Ma, Veltri, F, Arturi, F, Succurro, E, Sesti, G, Gualtieri, U, Perticone, F, Sciacqua, A, Quero, M, Bagnato, C, Loria, P, Becchi, Ma, Martucci, G, Fantuzzi, A, Maurantonio, M, Corinaldesi, R, De Giorgio, R, Serra, M, Grasso, V, Ruggeri, E, Carozza, Lm, Pignatti, F., 337. Franchi C, Salerno F, Conca A, Djade CD, Tettamanti M, Pasina L, Corrao S, Marengoni A, Marcucci M, Mannucci PM, Nobili A. REPOSI Investigator, Bernardi M, Borghi C, Strocchi E, Zoli M, Bolondi L, Corinaldesi R, De Giorgio R, Franchi C, Salerno F, Conca, A, Djade, Cd, Tettamanti, M, Pasina, L, Corrao, S, Marengoni, A, Marcucci, M, Mannucci, Pm, Nobili, A, Zanetti, Michela, Franchi, Carlotta, Salerno, Francesco, Conca, Alessio, Djade, Codjo D., Tettamanti, Mauro, Pasina, Luca, Corrao, Salvatore, Marengoni, Alessandra, Marcucci, Maura, Mannucci, Pier Mannuccio, Nobili, Alessandro, Sparacio, Eleonora, Alborghetti, Stefania, Di Costanzo, Rosa, Prisco, Domenico, Silvestri, Elena, Cenci, Caterina, Barnini, Tommaso, Delitala, Giuseppe, Carta, Stefano, Atzori, Sebastiana, Guarnieri, Gianfranco, Spalluti, Annalisa, Serra, Maria Grazia, Bleve, Maria Antonietta, Vanoli, Massimo, Grignani, Giulia, Casella, Gianluca, Gasbarrone, Laura, Maniscalco, Giorgio, Gunelli, Massimo, Tirotta, Daniela, Brucato, Antonio, Ghidoni, Silvia, Di Corato, Paola, Bernardi, Mauro, Li Bassi, Silvia, Santi, Luca, Agnelli, Giancarlo, Iorio, Alfonso, Marchesini, Emanuela, Mannarino, Elmo, Lupattelli, Graziana, Rondelli, Pamela, Paciullo, Francesco, Fabris, Fabrizio, Carlon, Michela, Turatto, Francesca, Baroni, Maria Cristina, Zardo, Marianna, Manfredini, Roberto, Molino, Christian, Pala, Marco, Fabbian, Fabio, Nuti, Ranuccio, Valenti, Roberto, Ruvio, Martina, Cappelli, Silvia, Paolisso, Giuseppe, Rizzo, Mr, Laieta, Maria Teresa, Salvatore, Teresa, Sasso, Ferdinando Carlo, Utili, Riccardo, Mangoni, Emanuele Durante, Pinto, Daniela, Olivieri, Oliviero, Stanzial, Anna Maria, Fellin, Renato, Volpato, Stefano, Fotini, Siouli, Barbagallo, Mario, Dominguez, Ligia, Plances, Lidia, D'Angelo, Daniela, Rini, Giovanbattista, Mansueto, Pasquale, Pepe, Ilenia, Licata, Giuseppe, Calvo, Luigi, Valenti, Maria, Borghi, Claudio, Strocchi, Enrico, Rinaldi, Elisa Rebecca, Zoli, Marco, Fabbri, Elisa, Magalotti, Donatella, Auteri, Alberto, Pasqui, Anna Laura, Puccetti, Luca, Pasini, Franco Laghi, Capecchi, Pier Leopoldo, Bicchi, Maurizio, SabbÃ&nbsp, Carlo, Vella, Francesco Saverio, Marseglia, Alessandro, Luglio, Chiara Valentina, Palasciano, Giuseppe, Modeo, Maria Ester, Aquilino, Annamaria, Raffaele, Pallante, Pugliese, Stefania, Capobianco, Caterina, Postiglione, Alfredo, Barbella, Maria Rosaria, De Stefano, Francesco, Fenoglio, Luigi, Brignone, Chiara, Bracco, Christian, Giraudo, Alessia, Musca, Giuseppe, Cuccurullo, Olga, Cricco, Luigi, Fiorentini, Alessandra, Cappellini, Maria Domenica, Fabio, Giovanna, Seghezzi, Sonia, De Amicis, Margherita Migone, Fargion, Silvia, Bonara, Paola, Bulgheroni, Mara, Lombardi, Rosa, Magrini, Fabio, Massari, Ferdinando, Tonella, Tatiana, Peyvandi, Flora, Tedeschi, Alberto, Rossio, Raffaella, Moreo, Guido, Ferrari, Barbara, Roncari, Luisa, Monzani, Valter, Savojardo, Valeria, Folli, Christian, Magnini, Maria, Mari, Daniela, Rossi, Paolo Dionigi, Damanti, Sarah, Prolo, Silvia, Lilleri, Maria Sole, Micale, Giuliana, Podda, Mauro, Selmi, Carlo, Meda, Francesca, Accordino, Silvia, Monti, Valentina, Corazza, Gino Roberto, Miceli, Emanuela, Lenti, Marco Vincenzo, Padula, Donatella, Balduini, Carlo L., Bertolino, Giampiera, Provini, Stella, Quaglia, Federica, Murialdo, Giovanni, Bovio, Marta, Dallegri, Franco, Ottonello, Luciano, Quercioli, Alessandra, Barreca, Alessandra, Secchi, Maria Beatrice, Ghelfi, Davide, Chin, Wu Sheng, Carassale, Laura, Caporotundo, Silvia, Anastasio, Luigi, Sofia, Lucia, Carbone, Maria, Traisci, Giancarlo, De Feudis, Lucrezia, Di Carlo, Silvia, Davã¬, Giovanni, Guagnano, Maria Teresa, Sestili, Simona, Bergami, Elisabetta, Rizzioli, Emanuela, Cagnoni, Carlo, Bertone, Luca, Manucra, Antonio, Buratti, Alberto, Tognin, Tiziana, Liberato, Nicola Lucio, Bernasconi, Giordano, Nardo, Barbara, Bianchi, Giovanni Battista, Benetti, Giampiero, Quagliolo, Michela, Centenaro, Giuseppe Riccardo, Purrello, Francesco, Di Pino, Antonino, Piro, Salvatore, Mancuso, Gerardo, Calipari, Daniela, Bartone, Mosã, Gullo, Francesco, Cortellaro, Michele, Magenta, Marina, Perego, Francesca, Meroni, Maria Rachele, Cicardi, Marco, Magenta, Antonio Gidaro Marina, Sacco, Andrea, Bonelli, Antonio, Dentamaro, Gaetano, Rozzini, Renzo, Falanga, Lina, Giordano, Alessandro, Perin, Paolo Cavallo, Lorenzati, Bartolomeo, Gruden, Gabriella, Bruno, Graziella, Montrucchio, Giuseppe, Greco, Elisabetta, Tizzani, Pietro, Fera, Giacomo, Di Luca, Maria Loreta, Renna, Donatella, Perciccante, Antonio, Coralli, Alessia, Tassara, Rodolfo, Melis, Deborah, Rebella, Lara, Menardo, Giorgio, Bottone, Stefania, Sferrazzo, Elsa, Ferri, Claudio, Striuli, Rinaldo, Scipioni, Rosa, Salmi, Raffaella, Gaudenzi, Piergiorgio, Gamberini, Susanna, Ricci, Franco, Morabito, Cosimo, Fava, Roberto, Semplicini, Andrea, Gottardo, Lucia, Vendemiale, Gianluigi, Serviddio, Gaetano, Forlano, Roberta, Bolondi, Luigi, Rasciti, Leonardo, Serio, Ilaria, Masala, Cesare, Mammarella, Antonio, Raparelli, Valeria, Fanelli, Filippo Rossi, Delfino, Massimo, Amoroso, Antonio, Violi, Francesco, Basili, Stefania, Perri, Ludovica, Serra, Pietro, Fontana, Vincenzo, Falcone, Marco, Landolfi, Raffaele, Grieco, Antonio, Gallo, Antonella, ZuccalÃ&nbsp, Giuseppe, Franceschi, Francesco, De Marco, Guido, Chiara, Cordischi, Marta, Sabbatini, Bellusci, Martino, Setti, Donatella, Pedrazzoli, Filippo, Romanelli, Giuseppe, Pirali, Caterina, Amolini, Claudia, Rosei, Enrico Agabiti, Rizzoni, Damiano, Castoldi, Luana, Picardi, Antonio, Gentilucci, Umberto Vespasiani, Mazzarelli, Chiara, Gallo, Paolo, Guasti, Luigina, Castiglioni, Luana, Maresca, Andrea, Squizzato, Alessandro, Contini, Sara, Molaro, Marta, Annoni, Giorgio, Corsi, Maurizio, Zazzetta, Sara, Bertolotti, Marco, Mussi, Chiara, Scotto, Roberto, Ferri, Maria Alice, Veltri, Francesca, Arturi, Franco, Succurro, Elena, Sesti, Giorgio, Gualtieri, Umberto, Perticone, Francesco, Sciacqua, Angela, Quero, Michele, Bagnato, Chiara, Loria, Paola, Becchi, Maria Angela, Martucci, Gianfranco, Fantuzzi, Alessandra, Maurantonio, Mauro, Corinaldesi, Roberto, De Giorgio, Roberto, Serra, Mauro, Grasso, Valentina, Ruggeri, Eugenio, Carozza, Lorenzo Mauro, Pignatti, Fabio, Franchi, C, Salerno, F, Djade, C, Mannucci, P, Prisco, D, Silvestri, E, Cenci, C, Barnini, T, Delitala, G, Carta, S, Attori, S, Guarnieri, G, Zanetti, M, Spallati, A, Serra, M, Bleve, M, Vanoli, M, Grignani, G, Casella, G, Gasbarrone, L, Maniscalco, G, Gunelli, M, Tirotta, D, Brucato, A, Ghidoni, S, Di Corato, P, Bernardi, M, Li Bassi, S, Santi, L, Agnelli, G, Iorio, A, Marchesini, E, Mannarino, E, Lupattelli, G, Rondelli, P, Maciullo, F, Fabris, F, Carlon, M, Turatto, F, Baroni, M, Zardo, M, Manfredini, R, Molino, C, Pala, M, Fabbian, F, Nuti, R, Valenti, R, Ruvio, M, Cappelli, S, Paolisso, G, Rizzo, M, Laieta, M, Salvatore, T, Sasso, F, Utili, R, Durante Mangoni, E, Pinto, D, Olivieri, O, Stanzial, A, Fellin, R, Volpato, S, Fotini, S, Barbagallo, M, Dominguez, L, Plances, L, D'Angelo, D, Rini, G, Mansueto, P, Pepe, I, Licata, G, Calvo, L, Valenti, M, Borghi, C, Strocchi, E, Rinaldi, E, Zoli, M, Fabbri, E, Magalotti, D, Auteri, A, Pasqui, A, Puccetti, L, Laghi Pasini, F, Capecchi, P, Bicchi, M, Sabbà, C, Vella, F, Marseglia, A, Luglio, C, Palasciano, G, Modeo, M, Aquilino, A, Raffaele, P, Pugliese, S, Capobianco, C, Postiglione, A, Barbella, M, De Stefano, F, Fenoglio, L, Brignone, C, Bracco, C, Girando, A, Musca, G, Cuccurullo, O, Cricco, L, Fiorentini, A, Cappellini, M, Fabio, G, Seghezzi, S, Migone De Amicis, M, Fargion, S, Bonara, P, Bulgheroni, M, Lombardi, R, Magrini, F, Massari, F, Tonella, T, Peyvandi, F, Tedeschi, A, Rossio, R, Moreo, G, Ferrari, B, Roncari, L, Monzani, V, Savojardo, V, Folli, C, Magnini, M, Mari, D, Rossi, P, Damanti, S, Prolo, S, Lilleri, M, Micale, G, Podda, M, Selmi, C, Meda, F, Accordino, S, Monti, A, Corazza, G, Miceli, E, Lenti, M, Padula, D, Balduini, C, Bertolino, G, Provini, S, Quaglia, F, Murialdo, G, Bovio, M, Dallegri, F, Ottonello, L, Quercioli, A, Barreca, A, Secchi, M, Guelfi, D, Chin, W, Carassale, L, Caporotundo, S, Anastasio, L, Sofia, L, Carbone, M, Traisci, G, De Feudis, L, Di Carlo, S, Davì, G, Guagnano, M, Sestili, S, Bergami, E, Rizzioli, E, Cagnoni, C, Bertone, L, Manucra, A, Buratti, A, Tognin, T, Liberato, N, Bernasconi, G, Nardo, B, Bianchi, G, Giaquinto, S, Benetti, G, Quagliolo, M, Centenaro, G, Purrello, F, Di Pino, A, Piro, S, Mancuso, G, Calipari, D, Bartone, M, Gullo, F, Cortellaro, M, Magenta, M, Perego, F, Meroni, M, Cicardi, M, Gigaro, A, Sacco, A, Bonelli, A, Dentamaro, G, Rozzini, R, Falanga, L, Giordano, A, Cavallo Perin, P, Lorenzati, B, Gruden, G, Bruno, G, Montrucchio, G, Greco, E, Tizzoni, P, Fera, G, Di Luca, M, Renna, D, Perciccante, A, Coralli, A, Tassara, R, Melis, D, Rebella, L, Menardo, G, Bottone, S, Sferruzzo, E, Ferri, C, Striuli, R, Scipioni, R, Salmi, R, Gaudenzi, P, Gamberini, S, Ricci, R, Morabito, C, Fava, R, Semplicini, A, Gottardo, L, Vendemiale, G, Serviddio, G, Forlano, R, Bolondi, L, Rasciti, L, Serio, I, Masala, C, Mammarella, A, Raparelli, V, Rossi Fanelli, F, Delfino, M, Amoroso, A, Violi, F, Basili, S, Perri, L, Serra, P, Fontana, V, Falcone, M, Landolfi, R, Grieco, A, Gallo, A, Zuccalà, G, Franceschi, F, De Marco, G, Chiara, C, Marta, S, Bellusci, M, Setti, D, Pedrazzoli, F, Romanelli, G, Pirali, C, Amolini, C, Agabiti Rosei, E, Rizzoni, D, Castoldi, L, Picardi, A, Vespasiani Gentilucci, U, Mazzarelli, C, Gallo, P, Guasti, L, Castiglioni, L, Maresca, A, Squizzato, A, Contini, S, Molaro, M, Annoni, G, Corsi, M, Zazzetta, S, Bertolotti, M, Mussi, C, Scotto, R, Ferri, M, Veltri, F, Arturi, F, Succurro, E, Sesti, G, Gualtieri, U, Perticone, F, Sciacqua, A, Quero, M, Bagnato, C, Loria, P, Becchi, M, Martucci, G, Fantuzzi, A, Maurantonio, M, Corinaldesi, R, De Giorgio, R, Grasso, V, Ruggeri, E, Carozza, L, Pignatti, F, Franchi, C., Salerno, F., Conca, A., Djade, C., Tettamanti, M., Pasina, L., Corrao, S., Marengoni, A., Marcucci, M., Mannucci, P., Nobili, A., and Mansueto, P.
Subjects: Male, Kidney Disease, Settore MED/09 - Medicina Interna, hyperuricemia, Comorbidities, chemistry.chemical_compound, Cardiovascular Disease, gout, elderly, Allopurinol, Elderly, Gout, Hyperuricemia, Outcomes, Age Factors, Aged, Aged, 80 and over, Cardiovascular Diseases, Chronic Disease, Comorbidity, Female, Hospital Mortality, Hospitalization, Humans, Kidney Diseases, Length of Stay, Treatment Outcome, Uric Acid, Internal Medicine, Medicine (all), 80 and over, Medicine, Age Factor, Outcome, OUTCOMES, comorbidity, Cohort, Comorbiditie, Human, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, allopurinol, NO, gout, Gout, allopurinol, hyperuricemia, comorbidities, outcomes, elderly, Internal medicine, Risk factor, Intensive care medicine, Adverse effect, ELDERLY, gout, allopurinol, hyperuricemia, comorbidities, outcomes, elderly, business.industry, nutritional and metabolic diseases, medicine.disease, chemistry, Uric acid, business
Abstract: Background: Increased serum uric acid has been considered a cardiovascular risk factor but no study has assessed its relation with hospital mortality or length of stay. On the basis of data obtained from a prospective registry, the prevalence of gout/hyperuricemia and its association with these and other clinical parameters was evaluated in an Italian cohort of elderly patients acutely admitted to internal medicine or geriatric wards. Methods: While the prevalence of gout was calculated by counting patients with this diagnosis hyperuricemia was inferred in patients taking allopurinol at hospital admission or discharge, on the assumption that this drug was only prescribed owing to the finding of high serum levels of uric acid. A series of clinical and demographic variables were evaluated for their association with gout/hyperuricemia. Results: Of 1380 patients, 139 (10%) had a diagnosis of gout or were prescribed allopurinol. They had more co-morbidities (7.0 vs 5.6; P < 0.0001) and consumed more drugs (6.8 vs 5.0; < b 0.0001). The CIRS (co-morbidity index) was worse in these patients (OR 1.28 95% CI 1.15-1.41). Multivariable regression analysis showed that only renal and heart failures were independently associated with gout/allopurinol intake. Moreover, this combined event was associated with an increased risk of adverse events during hospitalization (OR 1.66, 95% CI 1.16-2.36), but not with the risk of re-hospitalization, length of hospital stay or death. Conclusions: Gout/allopurinol intake has a high prevalence in elderly patients acutely admitted to hospital and are associated with renal and cardiovascular diseases, an increased rate of adverse events and a high degree of drug consumption. In contrast, this finding did not affect the length of hospitalization nor hospital mortality.
Published: 2014

41. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

Author: Nieves Martell-Claros, Alberto Zanchetti, Fernando Pinto, Yuqing Zhang, Michel Burnier, Krzysztof Narkiewicz, Stéphane Laurent, Serap Erdine, Peter M. Nilsson, Antonella Zambon, Giovanni Corrao, Grzegorz Bilo, Anna F. Dominiczak, Enrico Agabiti-Rosei, Maciej Banach, Josep Redon, Chengbin Xu, Hengge Xie, Athanasios J. Manolis, Vincenzo Silani, Lisheng Liu, Xuezhong Zhang, Marco Stramba-Badiale, Bojan Jelaković, Dingliang Zhu, Luis M. Ruilope, John T. O'Brien, Guido Grassi, Gangzhi Wei, Ting Rui Guan, Dror Dicker, Dragan Lovic, Roland E. Schmieder, Csaba Farsang, Antonio Coca, Yuriy Sirenko, Zhaosu Wu, Rok Accetto, Gianfranco Parati, Gary A. Ford, Lorenza Scotti, Hayyan Wang, Xin-Hua Zhang, Arman Postadzhiyan, Jose L. Rodicio, Alexandra Konradi, Eivind Berge, Margus Viigimaa, Renata Cifkova, Giuseppe Mancia, Philippos Stylianou, Irina Lazareva, Maria Dorobantu, Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Guan, T, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, and Ford, G
Subjects: Male, medicine.medical_specialty, China, Physiology, Blood Pressure, law.invention, chemistry.chemical_compound, Cognition, Randomized controlled trial, law, Recurrence, Internal medicine, Internal Medicine, medicine, Secondary Prevention, blood pressure, cognitive decline, low-density lipoprotein cholesterol, randomized controlled trial, secondary prevention, stroke, Dementia, Humans, Prospective Studies, Cognitive decline, Prospective cohort study, Stroke, Antihypertensive Agents, Aged, Ldl cholesterol, Cholesterol, business.industry, Blood Pressure Determination, Cholesterol, LDL, lipoprotein cholesterol, randomized controlled trial, secondary prevention, stroke, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, blood pressure, cognitive decline, low-density, Europe, Blood pressure, chemistry, Ischemic Attack, Transient, Hypertension, Physical therapy, Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, Cognition Disorders
Abstract: BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design. PROTOCOL DESIGN:: The European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial is a prospective multinational, randomized trial with a 3×2 factorial design comparing: three different SBP targets (1
Published: 2014

42. Midwall Mechanics Are Improved After Regression of Hypertensive Left Ventricular Hypertrophy and Normalization of Chamber Geometry

Author: Giuseppe Mancia, Bruno Trimarco, Cesare Cuspidi, Lorena Sampieri, Gerard P. Aurigemma, Stefano Perlini, Maria Lorenza Muiesan, Enrico Agabiti-Rosei, Perlini, S, Muiesan, M, Cuspidi, C, Sampieri, L, Trimarco, B, Aurigemma, G, Agabiti Rosei, E, and Mancia, G
Subjects: Adult, Male, medicine.medical_specialty, Heart disease, Hemodynamics, Blood Pressure, Midwall mechanics, regression oleft ventricular hypertrophy, Muscle hypertrophy, Hydrochlorothiazide, Physiology (medical), Internal medicine, medicine, Humans, Systole, Ventricular remodeling, Antihypertensive Agents, Aged, Ventricular Remodeling, business.industry, Lisinopril, Mechanics, Middle Aged, medicine.disease, Myocardial Contraction, Blood pressure, Heart Function Tests, Hypertension, Cardiology, Female, Hypertrophy, Left Ventricular, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: Background —It is still unclear whether substantial regression of hypertensive left ventricular hypertrophy (LVH) and normalization of chamber geometry are associated with improved left ventricular (LV) myocardial function. Methods and Results —Midwall mechanics were evaluated in 152 patients undergoing 1 year of effective antihypertensive treatment. Two-dimensionally directed M-mode echocardiography was performed as follows: (1) after a 4-week placebo “run-in” period, (2) after 1 year of treatment with 20 mg/d lisinopril (alone or associated with 12.5 to 25 mg/d hydrochlorothiazide), and (3) after a final 1-month placebo period to allow blood pressure (24-hour average ambulatory monitoring) to return to pretreatment levels. Treatment-induced reductions in blood pressure (from 149±16/95±11 to 131±12/83±10 mm Hg, P 2 , P 2 , P P P Conclusions —Regression of concentric LVH is associated with an improvement of midwall systolic function, which is more dependent on the normalization of LV geometry than on the reduction in LV systolic stress.
Published: 2001

43. Off-Patent Generic Medicines vs. Off-Patent Brand Medicines for Six Reference Drugs: A Retrospective Claims Data Study from Five Local Healthcare Units in the Lombardy Region of Italy

Author: Claudio Mencacci, Roberto Trevisan, Giorgio L Colombo, Carlomaurizio Montecucco, Enrico Agabiti-Rosei, Alberto Margonato, Colombo, G, Agabiti-Rosei, E, Margonato, A, Mencacci, C, Montecucco, C, Trevisan, R, Colombo Giorgio, L., Agabiti Rosei, Enrico, Margonato, Alberto, Mencacci, Claudio, Montecucco Carlo, Maurizio, and Trevisan, Roberto
Subjects: medicine.medical_specialty, Alternative medicine, MEDLINE, lcsh:Medicine, Nonprescription Drugs, Pharmacology, Documentation, Propafenone, Retrospective Studie, Claims data, Sertraline, Health care, medicine, Drugs, Generic, Humans, lcsh:Science, Retrospective Studies, Multidisciplinary, Health economics, Alendronate, business.industry, lcsh:R, Economic benefits, Metformin, Clinical Practice, Nonprescription Drug, Italy, Family medicine, lcsh:Q, Amlodipine, business, Human, Research Article
Abstract: The scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent generic drugs in clinical practice seems to be limited in Italy as yet. Methods: We compared differences in outcomes between off-patent generic drugs and off-patent brand drugs in real clinical practice. The outcomes were: persistence and compliance with therapy, mortality, and other health resources consumption (hospitalizations, specialist examinations, other drugs) and total costs. Retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASLs - Aziende Sanitarie Locali) in the Lombardy Region of Italy. Data from the five ASLs were aggregated through a meta-analysis, which produced an estimate indicator of the mean or percentage difference between the two groups (branded vs. generic) and their respective significance tests. The therapeutic areas and studied drugs were: diabetes: metformin - A10BA02; hypertension: amlodipine - C08CA01; dyslipidemia: simvastatin - C10AA01; psychiatry: sertraline - N06AB06; cardiology: propafenone - C01BC03; osteoporosis: alendronate - M05BA04. Results: The 5 Local Healthcare Units (ASL) represent a population of 3,847,004 inhabitants. The selected sample included 347,073 patients, or 9.02% of the total ASL population; 67% of the patients were treated with off-patent brand drugs. The average age was 68 years, with no difference between the two groups. After 34 months of observation, compliance and persistence were in favor to generic drugs in all therapeutic areas and statistically significant in the metformin, amlodipine, simvastatin, and sertraline groups. The clinical outcomes (hospitalizations, mortality, and other health costs) show no statistically significant differences between off-patent generic vs. off-patent brand medicines. Conclusions: Off-patent generic drugs appear to be a therapy option of choice in Italy as well, based on clinical outcomes and economic consequences, both for the National Health Service and patients, considering that the price difference between brand and generic drugs is completely charged on patients.
Published: 2013

44. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study)

Author: Gianfranco, Parati, Stefano, Omboni, Angelo, Compare, Enzo, Grossi, Edward, Callus, Achille, Venco, Maurizio, Destro, Giuseppe, Villa, Paolo, Palatini, Enrico Agabiti, Rosei, Simonetta, Scalvini, Stefano, Taddei, Dario, Manfellotto, Stefano, Favale, Carmine, De Matteis, Michele, Guglielmi, Laura, Lonati, Francesco, Della Rosa, Ellen, Tosazzi, Anna Maria, Grandi, Andrea Maria, Maresca, Christian, Mongiardi, Micaela, Mare, Alessandra Rossi, Ricci, Francesca, Cagnoni, Joannhe, Georgatos, Valeria, Besostri, Viviana, Ferrari, Ombretta, Omodeo, Francesca, Dorigatti, Elisa, Bonso, Chiara, Guarnieri, Lorenza, Muiesan, Anna, Paini, Deborah, Stassaldi, Angelo, Cinelli, Palmira, Bernocchi, Silvana, Rocchi, Armando, Magagna, Lorenzo, Ghiadoni, Irene, Del Frate, Francesca, Boresi, Antonella, Guidi, Maria Antonietta, Re, Luisa, Pellicciotti, Antonia, Florio, Giuliana, Morani, Silvana, Di Lillo, Antonietta, Ambrosio, Antonio, Casciello, Maria, Quaglia, Cinzia, Forleo, Maria Annunziata, Ardito, Stefania, Gerunda, Mariligia, Panunzio, Parati, G, Omboni, S, Compare, A, Grossi, E, Callus, E, Venco, A, Destro, M, Villa, G, Palatini, P, Agabiti Rosei, E, Scalvini, S, Taddei, S, Manfellotto, D, Favale, S, De Matteis, C, and Guglielmi, M
Subjects: Telemedicine, medicine.medical_specialty, Medicine (miscellaneous), Anxiety, law.invention, Medication Adherence, Study Protocol, Randomized controlled trial, Clinical Protocols, law, Settore M-PSI/08 - Psicologia Clinica, Outcome Assessment, Health Care, medicine, Humans, Pharmacology (medical), Personality traits, Intensive care medicine, Depression (differential diagnoses), Protocol (science), Metabolic Syndrome, Hypertension, Blood pressure, Home blood pressure telemonitoring, Adherence, Anxiety, Depression, Personality traits, lcsh:R5-920, Hypertension, blood pressure, home blood pressure telemonitoring, adherence, anxiety, depression, personality traits, business.industry, Depression, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Blood Pressure Monitoring, Ambulatory, medicine.disease, Home blood pressure telemonitoring, Blood pressure, Adherence, Ambulatory, medicine.symptom, Metabolic syndrome, business, lcsh:Medicine (General)
Abstract: Background Inadequate blood pressure control and poor adherence to treatment remain among the major limitations in the management of hypertensive patients, particularly of those at high risk of cardiovascular events. Preliminary evidence suggests that home blood pressure telemonitoring (HBPT) might help increasing the chance of achieving blood pressure targets and improve patient’s therapeutic adherence. However, all these potential advantages of HBPT have not yet been fully investigated. Methods/design The purpose of this open label, parallel group, randomized, controlled study is to assess whether, in patients with high cardiovascular risk (treated or untreated essential arterial hypertension - both in the office and in ambulatory conditions over 24 h - and metabolic syndrome), long-term (48 weeks) blood pressure control is more effective when based on HBPT and on the feedback to patients by their doctor between visits, or when based exclusively on blood pressure determination during quarterly office visits (conventional management (CM)). A total of 252 patients will be enrolled and randomized to usual care (n=84) or HBPT (n=168). The primary study endpoint will be the rate of subjects achieving normal daytime ambulatory blood pressure targets ( Discussion The TELEBPMET Study will show whether HBPT is effective in improving blood pressure control and related medical and economic outcomes in hypertensive patients with metabolic syndrome. It will also provide a comprehensive understanding of the psychological determinants of medication adherence and blood pressure control of these patients. Trial registration Clinical Trials.gov: NCT01541566
Published: 2013

45. Echocardiography in Hypertension: a Call for Standardization from the Working Group on Heart and Hypertension of the Italian Society of Hypertension

Author: Massimo Salvetti, Giuseppe Schillaci, Maria Lorenza Muiesan, Cesare Cuspidi, Nicola De Luca, Enrico Agabiti-Rosei, Cuspidi, C, Muiesan, Ml, DE LUCA, Nicola, Salvetti, M, Agabiti Rosei, E, Schillaci, G., Muiesan, M, De Luca, N, and Schillaci, G
Subjects: medicine.medical_specialty, Cost-Benefit Analysis, Heart Ventricles, Diagnostic accuracy, Blood Pressure, Sensitivity and Specificity, Electrocardiography, Left atrial, Risk Factors, Internal medicine, Ultrasound, Clinical information, Internal Medicine, medicine, Humans, Heart Atria, Intensive care medicine, LV hypertrophy, Arterial Hypertension, medicine.diagnostic_test, business.industry, Left ventricular hypertrophy, Organ damage, Hypertrophy, Echocardiography in hypertension, Cardiovascular risk, medicine.disease, Hypertensive heart disease, Clinical Practice, Left ventricular hypertrophy, Echocardiography, Ultrasound, Arterial Hypertension, Organ damage, Cardiovascular risk, Hypertrophy, Blood pressure, Cardiovascular Diseases, Echocardiography, Hypertension, Practice Guidelines as Topic, cardiovascular system, Cardiology, Cardiology and Cardiovascular Medicine, business
Abstract: The variety of clinical information provided by the echocardiogram (i.e. assessment of left ventricular (LV) structure and geometry, systolic/diastolic function, left atrial and aortic size) in addition to its superior sensitivity for LV hypertrophy detection compared to electrocardiogram are strong arguments supporting the paramount importance of this technique in the assessment of hypertensive heart disease. A number of limitations of the echocardiographic technique, however, including lack of standardized/quantitative procedures, impair its diagnostic accuracy and cost-effectiveness. The aim of these recommendations is to provide a document on the minimum acceptable requirements for the clinical practice of echocardiography in the hypertensive setting and thus to improve the quality of this fundamental tool in the cardiovascular risk stratification of hypertensive patients. © 2013 Springer International Publishing.
Published: 2013

46. Metabolic syndrome and chronic kidney disease in high-risk Italian hypertensive patients: the I-DEMAND study

Author: Giacomo Deferrari, Massimo Volpe, Roberto Pontremoli, Gastone Leonetti, Enrico Agabiti Rosei, Bruno Trimarco, Achille C. Pessina, Francesca Viazzi, Ettore Ambrosioni, Giovanna Leoncini, F. V. Costa, Leoncini, G, Viazzi, F, Agabiti Rosei, E, Ambrosioni, E, Costa, Fv, Leonetti, G, Pessina, Ac, Trimarco, Bruno, Volpe, M, Deferrari, G, and Pontremoli, R.
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, Cross-sectional study, Population, Renal function, urologic and male genital diseases, glomerular filtration rate, metabolic syndrome, albuminuria, hypertension, chronic kidney disease, Young Adult, Internal medicine, medicine, Diabetes Mellitus, Prevalence, Albuminuria, Humans, "metabolic syndrome", Renal Insufficiency, Chronic, education, Aged, Aged, 80 and over, Metabolic Syndrome, education.field_of_study, business.industry, Confounding, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, Endocrinology, Cross-Sectional Studies, Logistic Models, Italy, Nephrology, Hypertension, Multivariate Analysis, Microalbuminuria, Female, Metabolic syndrome, medicine.symptom, business, Kidney disease, Glomerular Filtration Rate
Abstract: Background. Metabolic syndrome (MS) and chronic kidney disease (CKD) are well-known, independent predictors of increased cardiovascular risk. Both con- ditions are fairly prevalent in the general population. The aim of this study was to assess the relationship between MS or its individual components and CKD in an Italian population of hypertensive patients with normal or mildly to moderately impaired renal function under specialist care. Methods. A total of 2,916 patients (mean age 62 ± 11 years) among those enrolled in the I-DEMAND study were taken into consideration for this analysis. MS was defined according to the NCEP-ATP III criteria. CKD was defined as an estimated GFR (abbreviated MDRD equation)
Published: 2012

47. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension

Author: Costas Tsioufis, Krzysztof Narkiewicz, Roland E. Schmieder, Serap Erdine, Enrico Agabiti Rosei, Josep Redon, Giuseppe Mancia, Athanasios J. Manolis, Gregory Y.H. Lip, Renata Cifkova, Sverre E. Kjeldsen, Antonio Coca, Gianfranco Parati, Manolis, A, Agabiti Rosei, E, Coca, A, Cifkova, R, Erdine, S, Kjeldsen, S, Lip, G, Narkiewicz, K, Parati, G, Redon, J, Schmieder, R, Tsioufis, C, and Mancia, G
Subjects: medicine.medical_specialty, Physiology, macromolecular substances, Fibrosis, Risk Factors, Cardiovascular Disorder, Internal medicine, Thromboembolism, Atrial Fibrillation, Internal Medicine, medicine, Humans, cardiovascular diseases, Risk factor, Stroke, Societies, Medical, business.industry, Warfarin, Atrial fibrillation, Hypertension, atrial fibrillation, anticoagulants, antihypertensive treatment, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, Thrombosis, Europe, Blood pressure, Hypertension, Cardiology, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases the risk of stroke but its coexistence with high blood pressure leads to an abrupt increase of cardiovascular complications. Different risk models are available for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In all of them hypertension is present and is an important risk factor. Antihypertensive treatment may contribute to reduce this risk, and it seems some classes are superior to others in the prevention of new-onset atrial fibrillation and prevention of stroke. Antithrombotic treatment with warfarin is effective in the prevention of thromboembolic events, although quite recently, new classes of anticoagulants that do not require international normalized ratio monitoring have been introduced with promising results.
Published: 2011

48. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document

Author: Antonio Coca, Robert Fagard, Luis M. Ruilope, Ettore Ambrosioni, Pieter A. Van Zwieten, Anna F. Dominiczak, Mark J. Caulfield, Jose L. Rodicio, Michael H. Olsen, Margus Viigimaa, Enrico Agabiti-Rosei, Hermann Haller, Renata Cifkova, Josep Redon, Csaba Farsang, Guido Grassi, Karl H. Rahn, Serap Erdine, Sverre E. Kjeldsen, Harry A.J. Struijker-Boudier, Giuseppe Mancia, Athanasios J. Manolis, Michel Burnier, Krzysztof Narkiewicz, Stéphane Laurent, Roland E. Schmieder, Anthony M. Heagerty, Peter M. Nilsson, Denis Clement, Wolfgang Kiowski, Jean Michel Mallion, Alberto Zanchetti, Mancia, G, Laurent, S, Agabiti Rosei, E, Ambrosioni, E, Burnier, M, Caulfield, M, Cifkova, R, Clement, D, Coca, A, Dominiczak, A, Erdine, S, Fagard, R, Farsang, C, Grassi, G, Haller, H, Heagerty, A, Kjeldsen, S, Kiowski, W, Mallion, J, Manolis, A, Narkiewicz, K, Nilsson, P, Olsen, M, Rahn, K, Redon, J, Rodicio, J, Ruilope, L, Schmieder, R, Sruijker Boudier, H, Van Zwieten, P, Viigimaa, M, and Zanchetti, A
Subjects: medicine.medical_specialty, management arterial hypertension, Physiology, update, Renal function, Blood Pressure, Internal medicine, medicine, Internal Medicine, Humans, cardiovascular diseases, Antihypertensive Agents, Task force, business.industry, Hypertension Guideline, Hypertension management, General Medicine, Europe, Organ damage, Blood pressure, Hypertension, Practice Guidelines as Topic, cardiovascular system, Cardiology, MED/09 - MEDICINA INTERNA, business, Endothelin receptor, Cardiology and Cardiovascular Medicine
Abstract: Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Commit
Published: 2009

49. Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies

Author: Antonio Vittorino Gaddi, Ada Dormi, Sandro Muntoni, Alessandro Menotti, Stefano Remiddi, G. Cavera, Mariapaola Lanti, Alberto Zanchetti, Pierluigi Prati, Mario Motolese, Sergio Muntoni, Alberto Notarbartolo, Luigi Carratelli, Mario Mancini, Enrico Agabiti-Rosei, Maria Lorenza Muiesan, Menotti A, Lanti M, Agabiti-Rosei E, Carratelli L, Cavera G, Dormi A, Gaddi A, Mancini M, Motolese M, Muiesan ML, Muntoni S, Notarbartolo A, Prati P, Remiddi S, and Zanchetti A.
Subjects: Adult, Male, Risk, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Population, Medicine (miscellaneous), Risk Assessment, Diabetes Complications, Sex Factors, Predictive Value of Tests, Risk Factors, Software Design, Prevalence, Medicine, Humans, Risk factor, education, Aged, education.field_of_study, Nutrition and Dietetics, Framingham Risk Score, business.industry, Smoking, Absolute risk reduction, Age Factors, Middle Aged, Surgery, Risk Estimate, Cholesterol, Italy, Cardiovascular Diseases, Relative risk, Hypertension, Female, Cardiology and Cardiovascular Medicine, business, Risk assessment, Body mass index, Algorithms, Demography, Follow-Up Studies
Abstract: Background and aim The need to update tools for the estimate of cardiovascular risk prompted the “Gruppo di Ricerca per la Stima del Rischio Cardiovascolare in Italia” to produce a new chart and new software called Riskard 2005. Methods and results Data from 9 population studies in 8 Italian regions, for a grand total of 17,153 subjects (12,045 men and 5,108 women) aged 35–74 and for a total exposure of about 194,000 person/years were available. A chart for the estimate of cardiovascular risk (major coronary, cerebrovascular and peripheral artery disease events) in 10 years was produced for men and women aged 45–74 free from cardiovascular diseases. Risk factors employed in the estimate were sex, age (6 classes), systolic blood pressure (4 classes), serum cholesterol (5 classes), diabetes, and cigarette smoking (4 classes). Estimates were produced for absolute risk and for relative risk, the latter against levels expected in the general population that produced the risk functions. Software was produced for the separate estimate of major coronary, cerebrovascular and cardiovascular events (the latter made by coronary, cerebrovascular and peripheral artery disease of atherosclerotic origin) for follow-up at 5, 10 or 15 years, in men a women aged 35–74 years at entry and free from cardiovascular diseases. Risk factors employed here were sex, age, body mass index, mean physiological blood pressure, HDL cholesterol, non-HDL cholesterol, cigarette smoking, diabetes and heart rate. The output is based on several indicators: absolute risk, relative risk (as defined above), ideal risk (for a very favourable risk profile), biological age of risk, comparisons among the above indicators, the percent contribution of risk factors to the excess of estimated risk above the level of the ideal risk, and the description of trends in risk estimate in relation to repeated measurements. Conclusions These tools represent progress compared to similar tools produced some years ago by the same Research Group.
Published: 2005

50. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries

Author: Gianluca E.M. Boari, Maurizio Castellano, Maria Lorenza Muiesan, Enrico Agabiti-Rosei, Stefania Bonadonna, Damiano Rizzoni, Andrea Giustina, Carolina De Ciuceis, A. Burattin, I. Sleiman, Enzo Porteri, B. Cerudelli, Rizzoni, D, Porteri, E, Giustina, Andrea, DE CIUCEIS, C, Sleiman, I, Boari, Ge, M., Castellano, Muiesan, Ml, Bonadonna, S, Burattin, A, Cerudelli, B, and AGABITI ROSEI, E.
Subjects: Adult, medicine.medical_specialty, Vascular smooth muscle, Essential hypertension, Renovascular hypertension, Muscle hypertrophy, Subcutaneous Tissue, Internal medicine, Biopsy, Internal Medicine, Medicine, Humans, Insulin-Like Growth Factor I, Aged, medicine.diagnostic_test, business.industry, Arteries, Hypertrophy, Middle Aged, medicine.disease, Endocrinology, medicine.anatomical_structure, Blood pressure, Acromegaly, Hypertension, Vascular resistance, Vascular Resistance, business, Subcutaneous tissue
Abstract: Structural alterations of small resistance arteries in patients with essential hypertension (EH) are mostly characterized by inward eutrophic remodeling. However, we have observed the presence of hypertrophic remodeling in patients with renovascular hypertension, as well as in patients with noninsulin-dependent diabetes mellitus, suggesting a relevant effect of humoral growth factors on vascular structure. Growth hormone may stimulate in vitro proliferation of vascular smooth muscle cells. However, no data are presently available about small artery structure in acromegalic patients. Therefore, we have investigated the structure of subcutaneous small arteries in 12 normotensive (NT) subjects, in 12 EH subjects, and in 9 acromegalic patients (APs). All subjects underwent biopsy of the subcutaneous fat; then, small resistance arteries were dissected and mounted on a micromyograph. The normalized internal diameter, media thickness, media-to-lumen ratio, the media cross-sectional area together with remodeling, and growth indices were calculated. Demographic variables were similar in the three groups, except for blood pressure. The media-to-lumen ratio was significantly greater in EH and AP, compared with NT. No difference was observed between EH and AP. The media cross-sectional area was significantly greater in AP compared with EH and with NT. The calculation of remodeling and growth index suggests the presence of eutrophic remodeling in EH (growth index 0%) and of hypertrophic remodeling in AP (growth index 40%). In conclusion, our data suggest the presence of hypertrophic remodeling of subcutaneous small resistance arteries of AP, probably as a consequence of growth-stimulator properties of IGF-1.
Published: 2004

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

57 results on '"AGABITI‐ROSEI, E."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources